{
  "usdmVersion": "4.0",
  "generatedAt": "2026-01-02T03:03:03.437727",
  "generator": "Protocol2USDM v6.5.0",
  "study": {
    "id": "8ddf13fc-b9d3-45c6-ae25-7e9c93186bc2",
    "instanceType": "Study",
    "versions": [
      {
        "id": "9c825cff-12dd-4c3b-91d6-d59225ee5e92",
        "instanceType": "StudyVersion",
        "versionIdentifier": "1.0",
        "studyDesigns": [
          {
            "id": "0ce27459-2199-4e30-ba07-9fa66ce577cb",
            "name": "Study Design",
            "rationale": "Protocol-defined study design for investigating efficacy and safety",
            "instanceType": "InterventionalStudyDesign",
            "blindingSchema": {
              "id": "72972f47-177e-452e-81d7-7fc3147946d8",
              "standardCode": {
                "id": "8848eb66-683a-4887-8a71-97d39eee3be6",
                "code": "Open Label",
                "codeSystem": "http://www.cdisc.org",
                "codeSystemVersion": "2024-09-27",
                "decode": "Open Label",
                "instanceType": "Code"
              },
              "instanceType": "AliasCode"
            },
            "randomizationType": {
              "code": "Non-Randomized"
            },
            "arms": [
              {
                "id": "f6e6287f-1aaf-4912-98d5-3d2ba19a8434",
                "name": "ALXN1840 Treatment",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "All participants receive ALXN1840, starting at 15 mg/day for approximately 28 days, then titrating up to 30 mg/day from Day 29.",
                "type": {
                  "id": "C174266",
                  "code": "C174266",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Investigational Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "c99f8a3f-653a-4dd0-8b76-199e5431e36f",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              }
            ],
            "studyCohorts": [
              {
                "id": "08a55563-af30-43ae-a1bf-6a388a3bee6a",
                "name": "Cohort 1 (treatment experienced)",
                "instanceType": "StudyCohort",
                "characteristic": "Patients who have received WD therapy for > 28 days"
              },
              {
                "id": "05e6dc5e-e62e-4eb8-8349-abd64657bac9",
                "name": "Cohort 2 (treatment naïve)",
                "instanceType": "StudyCohort",
                "characteristic": "Patients who have received WD therapy for ≤ 28 days"
              }
            ],
            "studyCells": [
              {
                "id": "54580359-5dba-4902-a48b-5f35c99a2177",
                "armId": "f6e6287f-1aaf-4912-98d5-3d2ba19a8434",
                "epochId": "d8b8efc8-44c2-4a07-84b6-3ccdad6b2d94",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "283e8a15-7e35-426f-a3b7-c3980eafebad",
                "armId": "f6e6287f-1aaf-4912-98d5-3d2ba19a8434",
                "epochId": "eeea3714-a600-4aad-b2f1-38dc3239e12a",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "ebec83f2-3871-43a6-83ad-797911412c42",
                "armId": "f6e6287f-1aaf-4912-98d5-3d2ba19a8434",
                "epochId": "e5686af3-668e-48a8-a6bd-59a463c3254c",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "2d82d1a4-f76a-4360-a1f3-47dd975eb4cc",
                "armId": "f6e6287f-1aaf-4912-98d5-3d2ba19a8434",
                "epochId": "ff458dc1-86b0-40b8-8a75-7e7316ba5261",
                "elementIds": [],
                "instanceType": "StudyCell"
              }
            ],
            "eligibilityCriteria": [
              {
                "id": "0a7f38cb-3707-4746-a4d7-212ca41f7bda",
                "identifier": "1",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "1638fa46-bcbc-41c0-adca-447c28568b2c",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 1",
                "nextId": "fe8279bc-bdab-4efa-b8f0-46fabbced5f4"
              },
              {
                "id": "fe8279bc-bdab-4efa-b8f0-46fabbced5f4",
                "identifier": "2",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "17053051-439e-4f00-bf3a-8e4396ad8e95",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 2",
                "previousId": "0a7f38cb-3707-4746-a4d7-212ca41f7bda",
                "nextId": "4bb5e8e9-43d1-4026-87f4-17d6faffff4c"
              },
              {
                "id": "4bb5e8e9-43d1-4026-87f4-17d6faffff4c",
                "identifier": "3",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "039d9619-7d92-45e8-8f97-a45823d997f9",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 3",
                "previousId": "fe8279bc-bdab-4efa-b8f0-46fabbced5f4",
                "nextId": "ec776169-483a-415b-b9e5-0e119d3bb4ac"
              },
              {
                "id": "ec776169-483a-415b-b9e5-0e119d3bb4ac",
                "identifier": "4",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "cf04563e-036c-46e8-b80b-969113ebb922",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 4",
                "previousId": "4bb5e8e9-43d1-4026-87f4-17d6faffff4c",
                "nextId": "bf461cbb-42df-4fcf-9c23-88243ccd16b3"
              },
              {
                "id": "bf461cbb-42df-4fcf-9c23-88243ccd16b3",
                "identifier": "5",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "8eff3e8b-92b3-40f4-a4dc-7246e3b57a60",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 5",
                "previousId": "ec776169-483a-415b-b9e5-0e119d3bb4ac",
                "nextId": "08da0678-48db-49e0-84bf-e51b964747b7"
              },
              {
                "id": "08da0678-48db-49e0-84bf-e51b964747b7",
                "identifier": "6",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "7b31e86f-c773-4ced-9960-3e490cab8092",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 6",
                "previousId": "bf461cbb-42df-4fcf-9c23-88243ccd16b3",
                "nextId": "5f7f6503-57d8-4d88-becc-2087cfa148e7"
              },
              {
                "id": "5f7f6503-57d8-4d88-becc-2087cfa148e7",
                "identifier": "7",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "311fe08a-e228-4672-ab7c-dda541e4cb0e",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 7",
                "previousId": "08da0678-48db-49e0-84bf-e51b964747b7",
                "nextId": "56d257b1-b428-4766-8c24-73512b0d22ea"
              },
              {
                "id": "56d257b1-b428-4766-8c24-73512b0d22ea",
                "identifier": "8",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "bbf9a959-37ec-4b2d-8071-2776814c7bf1",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 8",
                "previousId": "5f7f6503-57d8-4d88-becc-2087cfa148e7",
                "nextId": "a0abf2dd-2a4a-41ad-89c5-5f482d500860"
              },
              {
                "id": "a0abf2dd-2a4a-41ad-89c5-5f482d500860",
                "identifier": "9",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "b5b0b8c0-abd5-411e-9fff-22ddb0d6b4f0",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 9",
                "previousId": "56d257b1-b428-4766-8c24-73512b0d22ea",
                "nextId": "3a55ae49-d905-4e84-bb18-05249bd4b6a3"
              },
              {
                "id": "3a55ae49-d905-4e84-bb18-05249bd4b6a3",
                "identifier": "10",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "7ac24719-3577-4ae1-b24b-44c44d235214",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 10",
                "previousId": "a0abf2dd-2a4a-41ad-89c5-5f482d500860",
                "nextId": "e80c6d81-2c2f-4f73-b872-2e2fed9a3790"
              },
              {
                "id": "e80c6d81-2c2f-4f73-b872-2e2fed9a3790",
                "identifier": "11",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "cf7414f0-32ee-4081-b1b9-cce608fde377",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 11",
                "previousId": "3a55ae49-d905-4e84-bb18-05249bd4b6a3",
                "nextId": "3b7fdac4-5015-4483-bee5-1cb9d4534bda"
              },
              {
                "id": "3b7fdac4-5015-4483-bee5-1cb9d4534bda",
                "identifier": "12",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ea477192-a83a-4b97-ae01-68c2e99d4e65",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 12",
                "previousId": "e80c6d81-2c2f-4f73-b872-2e2fed9a3790"
              },
              {
                "id": "71d904b2-330e-4299-984b-63e191ebf602",
                "identifier": "1",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "c951bcec-f670-4fd8-8b57-86490901962b",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 13",
                "nextId": "93cd3520-e947-4208-ac95-a0c288e5e7b9"
              },
              {
                "id": "93cd3520-e947-4208-ac95-a0c288e5e7b9",
                "identifier": "2",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "d3a96674-0cbc-4e37-bc8c-f8ec83d04fc1",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 14",
                "previousId": "71d904b2-330e-4299-984b-63e191ebf602",
                "nextId": "92486f7c-afdc-49fc-bfb3-cdc46767429d"
              },
              {
                "id": "92486f7c-afdc-49fc-bfb3-cdc46767429d",
                "identifier": "3",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "74d1b9fc-ec72-45ef-b163-8e8527e6372f",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 15",
                "previousId": "93cd3520-e947-4208-ac95-a0c288e5e7b9",
                "nextId": "5599195a-3f51-4991-85af-6c1b25a001d3"
              },
              {
                "id": "5599195a-3f51-4991-85af-6c1b25a001d3",
                "identifier": "4",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "3b9cc12c-901c-45aa-80a0-8102a7a664ad",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 16",
                "previousId": "92486f7c-afdc-49fc-bfb3-cdc46767429d",
                "nextId": "48c83eb2-2142-44e7-bbdb-2064779a7bdf"
              },
              {
                "id": "48c83eb2-2142-44e7-bbdb-2064779a7bdf",
                "identifier": "5",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "0e0e5033-9e12-4fba-a50b-c38977af7e3a",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 17",
                "previousId": "5599195a-3f51-4991-85af-6c1b25a001d3",
                "nextId": "1d9dff7b-8b46-441c-8f93-bc21283943bc"
              },
              {
                "id": "1d9dff7b-8b46-441c-8f93-bc21283943bc",
                "identifier": "6",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "c16a3780-0787-4a16-b577-ee4496da1e24",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 18",
                "previousId": "48c83eb2-2142-44e7-bbdb-2064779a7bdf",
                "nextId": "fbe130df-45e1-45df-b5eb-fe89df1e1a2c"
              },
              {
                "id": "fbe130df-45e1-45df-b5eb-fe89df1e1a2c",
                "identifier": "7",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "a79661cf-a8df-49af-8b62-03bc847181a8",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 19",
                "previousId": "1d9dff7b-8b46-441c-8f93-bc21283943bc",
                "nextId": "ab028223-db85-4a46-9423-bf44cfab2138"
              },
              {
                "id": "ab028223-db85-4a46-9423-bf44cfab2138",
                "identifier": "8",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "fe790e6e-0cf3-4e8f-a5e7-990a21949b20",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 20",
                "previousId": "fbe130df-45e1-45df-b5eb-fe89df1e1a2c",
                "nextId": "5e205e72-c488-4fcc-8d23-bc061a23f974"
              },
              {
                "id": "5e205e72-c488-4fcc-8d23-bc061a23f974",
                "identifier": "9",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "b22f123e-8dad-46df-abb9-7905cdf0a6b5",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 21",
                "previousId": "ab028223-db85-4a46-9423-bf44cfab2138",
                "nextId": "cce4cba8-e392-467e-a64c-6c2a9290e2a9"
              },
              {
                "id": "cce4cba8-e392-467e-a64c-6c2a9290e2a9",
                "identifier": "10",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "3fcdb86d-cbb3-46a8-b768-0c3d88fcbe11",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 22",
                "previousId": "5e205e72-c488-4fcc-8d23-bc061a23f974",
                "nextId": "62103e68-5cca-474f-b624-a8f2bde1e8a0"
              },
              {
                "id": "62103e68-5cca-474f-b624-a8f2bde1e8a0",
                "identifier": "11",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "6a7f9e37-1a50-416f-a968-f630c69febf0",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 23",
                "previousId": "cce4cba8-e392-467e-a64c-6c2a9290e2a9",
                "nextId": "c657a5ea-f250-4ade-b2fa-f5e0fa79256f"
              },
              {
                "id": "c657a5ea-f250-4ade-b2fa-f5e0fa79256f",
                "identifier": "12",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "c37abfa2-bf1c-4e0e-833b-aa9c75ee6bf4",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 24",
                "previousId": "62103e68-5cca-474f-b624-a8f2bde1e8a0",
                "nextId": "80093f59-6a7c-4726-8e56-978b751477eb"
              },
              {
                "id": "80093f59-6a7c-4726-8e56-978b751477eb",
                "identifier": "13",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "aff36a06-7b31-48aa-a352-114153ce0026",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 25",
                "previousId": "c657a5ea-f250-4ade-b2fa-f5e0fa79256f",
                "nextId": "0dc0d76e-5d25-4f87-b243-5b9e7fed3090"
              },
              {
                "id": "0dc0d76e-5d25-4f87-b243-5b9e7fed3090",
                "identifier": "14",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "dce31bd8-3f3f-42fd-b23c-10a38f958861",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 26",
                "previousId": "80093f59-6a7c-4726-8e56-978b751477eb",
                "nextId": "9593a60d-7950-4815-b1b8-1997ac8ec35f"
              },
              {
                "id": "9593a60d-7950-4815-b1b8-1997ac8ec35f",
                "identifier": "15",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "6e65c2ea-2e45-4dd3-8d72-04f69d101f44",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 27",
                "previousId": "0dc0d76e-5d25-4f87-b243-5b9e7fed3090",
                "nextId": "e87b0035-2c34-4f1a-b330-03e410ed26dc"
              },
              {
                "id": "e87b0035-2c34-4f1a-b330-03e410ed26dc",
                "identifier": "16",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "b48979e1-e5e6-4b09-90cc-cd683addcd81",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 28",
                "previousId": "9593a60d-7950-4815-b1b8-1997ac8ec35f",
                "nextId": "ed900baa-fe53-4f02-bcdc-3ca8432a01e8"
              },
              {
                "id": "ed900baa-fe53-4f02-bcdc-3ca8432a01e8",
                "identifier": "17",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "7b9249eb-a2d1-4e66-a258-73643e7aed71",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 29",
                "previousId": "e87b0035-2c34-4f1a-b330-03e410ed26dc",
                "nextId": "0eca0b12-3372-4123-9ec8-42635f575ec8"
              },
              {
                "id": "0eca0b12-3372-4123-9ec8-42635f575ec8",
                "identifier": "18",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "2a6d4a18-bee8-471c-82bb-e6a132db88eb",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 30",
                "previousId": "ed900baa-fe53-4f02-bcdc-3ca8432a01e8",
                "nextId": "9e1bfda1-6e56-41c7-8c4b-a0f600fea543"
              },
              {
                "id": "9e1bfda1-6e56-41c7-8c4b-a0f600fea543",
                "identifier": "19",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "789492d6-a34a-466e-b7c1-324eca1e9976",
                "instanceType": "EligibilityCriterion",
                "name": "Criterion 31",
                "previousId": "0eca0b12-3372-4123-9ec8-42635f575ec8"
              }
            ],
            "population": {
              "id": "0a4a6876-54ad-410e-9f2f-a8118c50ea68",
              "instanceType": "StudyDesignPopulation",
              "name": "Study Population",
              "description": "Target population for the study as defined by eligibility criteria",
              "includesHealthySubjects": false
            },
            "objectives": [
              {
                "id": "aad624fc-6622-4a2b-9ae8-278bc9473cc1",
                "name": "Primary Objective",
                "text": "Assess net copper balance with daily repeat-dose ALXN1840 treatment (15 mg and 30 mg) in participants with Wilson disease (WD)",
                "level": {
                  "id": "C85826",
                  "code": "C85826",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Primary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "ffe59592-88ba-4721-93aa-88af4747c7d0"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "6bfb6be5-7fd5-491b-b3a1-1b842c43f269",
                "name": "Secondary Objective 1",
                "text": "Assess change in copper balance in response to ALXN1840 15 mg/day and 30 mg/day during ALXN1840 accumulation and at steady state periods versus the pretreatment baseline in participants with WD",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "647fddec-b9e0-4f3f-9216-9baf7acaad72"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "085251a2-db84-478c-8708-78cc0cffa494",
                "name": "Secondary Objective 2",
                "text": "Investigate the effect of ALXN1840 (15 mg/day and 30 mg/day) on the disposition of copper in participants with WD",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "5cde5923-8be4-4d6f-812e-48cf6c1aba7a"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "96a51078-9014-4a94-b5a1-b810e927799e",
                "name": "Secondary Objective 3",
                "text": "Investigate the effect of ALXN1840 on the disposition of molybdenum at steady state at 15 mg/day and 30 mg/day in participants with WD",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "ad1eb421-8249-4c00-afad-6df39e7ac321"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "e221557d-7411-43ce-85de-2c03d8f3d76e",
                "name": "Secondary Objective 4",
                "text": "Assess steady-state total molybdenum balance as a measure of ALXN1840 15 mg/day and 30 mg/day in participants with WD",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "31267b05-695a-48ff-a11e-badfbea0bf9e"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "6856fbe3-7bef-4fad-9d21-63ca81399ca7",
                "name": "Secondary Objective 5",
                "text": "Assess accumulation of molybdenum with ALXN1840 treatment at 15 mg/day and 30 mg/day in participants with WD",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "d11117fc-dfc0-4160-9c30-84b4f5021f98"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "663bf00b-c2f5-4609-9465-3c23fa321968",
                "name": "Secondary Objective 6",
                "text": "Determine the steady-state plasma pharmacokinetic (PK) of total molybdenum and plasma ultrafiltrate (PUF) molybdenum (as surrogate measures of ALXN1840, 15 mg and 30 mg) in participants with WD",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "f4ab9369-bdf0-46bf-8191-32c6a792c02b"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "7bec95ff-638b-4ec4-b0f6-eedcca8143df",
                "name": "Safety Objective",
                "text": "Evaluate the safety and tolerability of repeated-dose administration of ALXN1840 15 mg/day and 30 mg/day in participants with WD",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "f429c248-da95-46cd-86ba-e7793d7b616e"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "9a6ba8d4-44e2-42cc-a46c-9c3f07b5eede",
                "name": "Exploratory Objective 1",
                "text": "Determine dose response of ALXN1840 15 mg/day and 30 mg/day for copper balance in participants with WD",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "b535aa25-822e-48fe-b918-0fa9eca95083"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "2e1aaec2-69b9-49b2-8460-fcb732d91237",
                "name": "Exploratory Objective 2",
                "text": "Determine the effect of treatment duration on copper balance in participants with WD",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "49584531-62f3-4620-b929-34e7081e721b"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "2b70b59b-6824-4373-9d97-bcab7b74451f",
                "name": "Exploratory Objective 3",
                "text": "Assess the effects of ALXN1840 on ceruloplasmin, ceruloplasmin-bound copper LBC profiles in plasma in participants with WD",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "5964a617-e122-49d7-9d22-82c6fc793260"
                ],
                "instanceType": "Objective"
              }
            ],
            "endpoints": [
              {
                "id": "ffe59592-88ba-4721-93aa-88af4747c7d0",
                "name": "Primary Endpoint",
                "text": "Mean daily copper balance where copper balance is measured by the calculated difference between copper intake (in food and drink) and copper output (in feces and urine) during ALXN1840 accumulation and steady-state periods for each dose",
                "level": {
                  "id": "C98772",
                  "code": "C98772",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Primary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "647fddec-b9e0-4f3f-9216-9baf7acaad72",
                "name": "Secondary Endpoint 1",
                "text": "Change in mean daily copper balance as measured by the calculated difference between copper intake (in food and drink) and copper output (in feces and urine) from pretreatment baseline (Days -4 through -1) and ALXN1840 accumulation and steady-state periods for each dose",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "5cde5923-8be4-4d6f-812e-48cf6c1aba7a",
                "name": "Secondary Endpoint 2",
                "text": "Copper quantified in food, drink, feces, and urine, including plasma total and labile bound copper (LBC) during ALXN1840 accumulation and steady-state periods for each dose",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacodynamic"
              },
              {
                "id": "ad1eb421-8249-4c00-afad-6df39e7ac321",
                "name": "Secondary Endpoint 3",
                "text": "Molybdenum quantified in food, drink, feces, and urine, plasma total molybdenum at ALXN1840 steady state",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacodynamic"
              },
              {
                "id": "31267b05-695a-48ff-a11e-badfbea0bf9e",
                "name": "Secondary Endpoint 4",
                "text": "Mean daily molybdenum balance as demonstrated through measurement of molybdenum intake (in food, drink and ALXN1840), and molybdenum output (feces and urine) representing ALXN1840 steady state",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacodynamic"
              },
              {
                "id": "d11117fc-dfc0-4160-9c30-84b4f5021f98",
                "name": "Secondary Endpoint 5",
                "text": "Accumulation of molybdenum as determined by molybdenum balance",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacokinetic"
              },
              {
                "id": "f4ab9369-bdf0-46bf-8191-32c6a792c02b",
                "name": "Secondary Endpoint 6",
                "text": "PK parameters for plasma total and PUF-molybdenum",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacokinetic"
              },
              {
                "id": "f429c248-da95-46cd-86ba-e7793d7b616e",
                "name": "Safety Endpoint",
                "text": "Safety parameters: \n• Treatment emergent adverse events (TEAEs)/serious adverse events (SAEs) \n• Clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis) \n• Physical examinations \n• Heart rate, intervals (PR, QRS, QT and QTc), and clinically significant electrocardiogram (ECG) findings as determined by triplicate 12-lead ECG \n• Vital sign assessments (blood pressure and heart rate)",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "b535aa25-822e-48fe-b918-0fa9eca95083",
                "name": "Exploratory Endpoint 1",
                "text": "Assess dose response of ALXN1840 on copper balance focusing on copper balance",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "49584531-62f3-4620-b929-34e7081e721b",
                "name": "Exploratory Endpoint 2",
                "text": "Determine the effect of time following initiation of ALXN1840 treatment on copper balance",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "5964a617-e122-49d7-9d22-82c6fc793260",
                "name": "Exploratory Endpoint 3",
                "text": "Ceruloplasmin, ceruloplasmin-bound copper, and LBC: Change in ceruloplasmin at Days 1, 8, 25, 29, 36, and Day 39 compared with predose",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Biomarker"
              }
            ],
            "studyInterventions": [
              {
                "id": "83d95517-2064-45ea-94a4-89f30757a0d8",
                "name": "ALXN1840",
                "role": {
                  "id": "be4c084a-760e-4d27-82d5-5836802c3ef2",
                  "code": "Investigational Product",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Investigational Product",
                  "instanceType": "Code"
                },
                "instanceType": "StudyIntervention",
                "description": "ALXN1840 (bis-choline tetrathiomolybdate; formerly known as WTX101) is a novel copper binding agent in development for the treatment of Wilson disease (WD).",
                "productIds": [
                  "71a31d51-a18c-4b74-acf4-7b92694b094d"
                ],
                "administrationIds": [
                  "6860472d-3745-4d9d-82e4-0291222b89e8"
                ]
              },
              {
                "id": "ef1f9a30-81f9-46b2-9be9-89af613dfd0e",
                "name": "Paracetamol/acetaminophen",
                "role": {
                  "id": "a83d6410-4a73-4721-98be-fbb85ccdbaac",
                  "code": "Concomitant Medication",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Concomitant Medication",
                  "instanceType": "Code"
                },
                "instanceType": "StudyIntervention",
                "description": "Permitted for use as an exception with the approval of the Investigator at doses of a maximum 1000 mg per day.",
                "administrationIds": [
                  "573be4aa-1fb3-45c5-bdeb-e99033ba9527"
                ]
              },
              {
                "id": "b19b199a-196b-4ede-add9-660c34145b00",
                "name": "Ibuprofen",
                "role": {
                  "id": "96b65a99-ab4c-45d8-9cca-e8869303a82e",
                  "code": "Concomitant Medication",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Concomitant Medication",
                  "instanceType": "Code"
                },
                "instanceType": "StudyIntervention",
                "description": "Permitted for use with caution and approval of the Investigator. The dose must not exceed 1200 mg in any 24-hour period.",
                "administrationIds": [
                  "00347f77-77d0-407d-98d8-e66b342d7305"
                ]
              }
            ],
            "model": {
              "id": "25416ee3-4a59-4cf7-a604-d0e7eedc426d",
              "code": "C82638",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Single Group Study",
              "instanceType": "Code"
            },
            "extensionAttributes": [
              {
                "id": "e74280d3-92f8-4eb7-a541-a25e4662d867",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-entityMaps",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"epochAliases\": {}, \"visitAliases\": {}}"
              },
              {
                "id": "951d26a2-cb85-498b-a7f0-aa23881a5273",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-classifiedIssues",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"severity\": \"warning\", \"category\": \"traversal_resolution\", \"message\": \"Traversal step 'SCREENING' could not be resolved to an epoch ID\", \"affectedPath\": \"$.traversalConstraints[].requiredSequence\", \"affectedIds\": [\"traversal_1\"], \"suggestion\": \"Create epoch for 'SCREENING' or map to existing epoch\"}, {\"severity\": \"warning\", \"category\": \"traversal_resolution\", \"message\": \"Traversal step 'RUN_IN' could not be resolved to an epoch ID\", \"affectedPath\": \"$.traversalConstraints[].requiredSequence\", \"affectedIds\": [\"traversal_1\"], \"suggestion\": \"Create epoch for 'RUN_IN' or map to existing epoch\"}, {\"severity\": \"warning\", \"category\": \"traversal_resolution\", \"message\": \"Traversal step 'BASELINE' could not be resolved to an epoch ID\", \"affectedPath\": \"$.traversalConstraints[].requiredSequence\", \"affectedIds\": [\"traversal_1\"], \"suggestion\": \"Create epoch for 'BASELINE' or map to existing epoch\"}, {\"severity\": \"warning\", \"category\": \"traversal_resolution\", \"message\": \"Traversal step 'TREATMENT' could not be resolved to an epoch ID\", \"affectedPath\": \"$.traversalConstraints[].requiredSequence\", \"affectedIds\": [\"traversal_1\"], \"suggestion\": \"Create epoch for 'TREATMENT' or map to existing epoch\"}, {\"severity\": \"warning\", \"category\": \"traversal_resolution\", \"message\": \"Traversal step 'MAINTENANCE' could not be resolved to an epoch ID\", \"affectedPath\": \"$.traversalConstraints[].requiredSequence\", \"affectedIds\": [\"traversal_1\"], \"suggestion\": \"Create epoch for 'MAINTENANCE' or map to existing epoch\"}, {\"severity\": \"warning\", \"category\": \"traversal_resolution\", \"message\": \"Traversal step 'FOLLOW_UP' could not be resolved to an epoch ID\", \"affectedPath\": \"$.traversalConstraints[].requiredSequence\", \"affectedIds\": [\"traversal_1\"], \"suggestion\": \"Create epoch for 'FOLLOW_UP' or map to existing epoch\"}, {\"severity\": \"warning\", \"category\": \"traversal_resolution\", \"message\": \"Traversal step 'END_OF_STUDY' could not be resolved to an epoch ID\", \"affectedPath\": \"$.traversalConstraints[].requiredSequence\", \"affectedIds\": [\"traversal_1\"], \"suggestion\": \"Create epoch for 'END_OF_STUDY' or map to existing epoch\"}, {\"severity\": \"warning\", \"category\": \"dosing_fragmentation\", \"message\": \"Dosing regimen has prose fragment as treatment name: 'for the...'\", \"affectedPath\": \"$.dosingRegimens[]\", \"affectedIds\": [\"dosing_1\"], \"suggestion\": \"Consolidate with parent intervention regimen\"}, {\"severity\": \"warning\", \"category\": \"dosing_fragmentation\", \"message\": \"Dosing regimen has prose fragment as treatment name: 'to \\nALXN1840...'\", \"affectedPath\": \"$.dosingRegimens[]\", \"affectedIds\": [\"dosing_4\"], \"suggestion\": \"Consolidate with parent intervention regimen\"}, {\"severity\": \"warning\", \"category\": \"dosing_fragmentation\", \"message\": \"Dosing regimen has prose fragment as treatment name: 'of ALXN1840...'\", \"affectedPath\": \"$.dosingRegimens[]\", \"affectedIds\": [\"dosing_7\"], \"suggestion\": \"Consolidate with parent intervention regimen\"}, {\"severity\": \"warning\", \"category\": \"dosing_fragmentation\", \"message\": \"Dosing regimen has prose fragment as treatment name: 'of approximately...'\", \"affectedPath\": \"$.dosingRegimens[]\", \"affectedIds\": [\"dosing_23\"], \"suggestion\": \"Consolidate with parent intervention regimen\"}, {\"severity\": \"warning\", \"category\": \"dosing_fragmentation\", \"message\": \"Dosing regimen has prose fragment as treatment name: 'to approximately...'\", \"affectedPath\": \"$.dosingRegimens[]\", \"affectedIds\": [\"dosing_24\"], \"suggestion\": \"Consolidate with parent intervention regimen\"}, {\"severity\": \"warning\", \"category\": \"dosing_fragmentation\", \"message\": \"Dosing regimen has prose fragment as treatment name: 'for both...'\", \"affectedPath\": \"$.dosingRegimens[]\", \"affectedIds\": [\"dosing_29\"], \"suggestion\": \"Consolidate with parent intervention regimen\"}, {\"severity\": \"warning\", \"category\": \"dosing_fragmentation\", \"message\": \"Dosing regimen has prose fragment as treatment name: 'of the...'\", \"affectedPath\": \"$.dosingRegimens[]\", \"affectedIds\": [\"dosing_42\"], \"suggestion\": \"Consolidate with parent intervention regimen\"}, {\"severity\": \"blocking\", \"category\": \"visit_window_conflict\", \"message\": \"Multiple visits mapped to Day 1: ['Early Termination', 'Day 1', 'EOS']\", \"affectedPath\": \"$.visitWindows[]\", \"affectedIds\": [\"visit_1\", \"visit_3\", \"visit_14\"], \"suggestion\": \"Re-derive targetDay from visit context or SoA position\"}, {\"severity\": \"warning\", \"category\": \"visit_window_conflict\", \"message\": \"Multiple visits mapped to Day 54: ['Day 54', 'End of Study']\", \"affectedPath\": \"$.visitWindows[]\", \"affectedIds\": [\"visit_12\", \"visit_13\"], \"suggestion\": \"Verify visit scheduling logic\"}]"
              },
              {
                "id": "433f9c92-424d-4adf-991b-7d2b9cc7d6bc",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-timeAnchors",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"anchor_llm_1\", \"definition\": \"Initiation of ALXN1840\", \"anchorType\": \"FirstDose\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"The accumulation period refers to time from initiation of ALXN1840 (Day 1) to expected steady state at Day 10, based on 5 times the half-life of 2 days.\"}, {\"id\": \"anchor_1\", \"definition\": \"Baseline visit/assessment\", \"anchorType\": \"Baseline\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"Baseline Day\"}, {\"id\": \"anchor_2\", \"definition\": \"Informed consent obtained\", \"anchorType\": \"InformedConsent\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"informed consent\"}, {\"id\": \"anchor_3\", \"definition\": \"procedure\", \"anchorType\": \"Custom\", \"timelineId\": null, \"dayValue\": 9, \"sourceText\": \"procedure\"}, {\"id\": \"anchor_collection_1\", \"definition\": \"24-hour collection period\", \"anchorType\": \"CollectionDay\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"24-hour urine\"}, {\"id\": \"anchor_collection_2\", \"definition\": \"24-hour collection period\", \"anchorType\": \"CollectionDay\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"24-hour collection\"}]"
              },
              {
                "id": "42770ded-c675-4ef9-9ad0-8764ee041825",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-repetitions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"rep_daily_1\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"daily urine\"}, {\"id\": \"rep_daily_2\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"once daily\"}, {\"id\": \"rep_daily_4\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"od\"}, {\"id\": \"rep_daily_67\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"OD\"}, {\"id\": \"rep_interval_1\", \"type\": \"Interval\", \"interval\": \"PT8H\", \"sourceText\": \"every \\n8 hours\"}, {\"id\": \"rep_window_1\", \"type\": \"Continuous\", \"startOffset\": \"P4D\", \"endOffset\": \"P1D\", \"sourceText\": \"Days -4 through -1\"}, {\"id\": \"rep_window_2\", \"type\": \"Continuous\", \"startOffset\": \"P7D\", \"endOffset\": \"P5D\", \"sourceText\": \"Day -7 through Day -5\"}, {\"id\": \"rep_window_3\", \"type\": \"Continuous\", \"startOffset\": \"P4D\", \"endOffset\": \"P1D\", \"sourceText\": \"Day -4 through Day -1\"}, {\"id\": \"rep_window_5\", \"type\": \"Continuous\", \"startOffset\": \"-P1D\", \"endOffset\": \"-P8D\", \"sourceText\": \"Day 1 through Day 8\"}, {\"id\": \"rep_window_6\", \"type\": \"Continuous\", \"startOffset\": \"P25D\", \"endOffset\": \"P39D\", \"sourceText\": \"Day 25 through Day 39\"}, {\"id\": \"rep_window_7\", \"type\": \"Continuous\", \"startOffset\": \"P1D\", \"endOffset\": \"P28D\", \"sourceText\": \"Day 1 through Day 28\"}, {\"id\": \"rep_window_8\", \"type\": \"Continuous\", \"startOffset\": \"P29D\", \"endOffset\": \"P39D\", \"sourceText\": \"Day 29 through Day 39\"}, {\"id\": \"rep_window_12\", \"type\": \"Continuous\", \"startOffset\": \"P25D\", \"endOffset\": \"P28D\", \"sourceText\": \"Days 25 through 28\"}, {\"id\": \"rep_window_13\", \"type\": \"Continuous\", \"startOffset\": \"P29D\", \"endOffset\": \"P39D\", \"sourceText\": \"Days 29 through 39\"}, {\"id\": \"rep_window_14\", \"type\": \"Continuous\", \"startOffset\": \"P4D\", \"endOffset\": \"P7D\", \"sourceText\": \"Days 4 - 7\"}, {\"id\": \"rep_window_15\", \"type\": \"Continuous\", \"startOffset\": \"-P26D\", \"endOffset\": \"-P28D\", \"sourceText\": \"Days 26 - 28\"}, {\"id\": \"rep_window_16\", \"type\": \"Continuous\", \"startOffset\": \"-P30D\", \"endOffset\": \"-P38D\", \"sourceText\": \"Days 30 - 38\"}, {\"id\": \"rep_window_17\", \"type\": \"Continuous\", \"startOffset\": \"P8D\", \"endOffset\": \"P9D\", \"sourceText\": \"Day -8 to Day 9\"}, {\"id\": \"rep_window_18\", \"type\": \"Continuous\", \"startOffset\": \"P23D\", \"endOffset\": \"P40D\", \"sourceText\": \"Day 23 to Day 40\"}, {\"id\": \"rep_window_19\", \"type\": \"Continuous\", \"startOffset\": \"P25D\", \"endOffset\": \"P28D\", \"sourceText\": \"Day 25 through Day 28\"}, {\"id\": \"rep_window_20\", \"type\": \"Continuous\", \"startOffset\": \"P36D\", \"endOffset\": \"P39D\", \"sourceText\": \"Day 36 through Day 39\"}, {\"id\": \"rep_window_22\", \"type\": \"Continuous\", \"startOffset\": \"P7D\", \"endOffset\": \"P5D\", \"sourceText\": \"Day -7 through \\nDay -5\"}, {\"id\": \"rep_window_29\", \"type\": \"Continuous\", \"startOffset\": \"P1D\", \"endOffset\": \"P9D\", \"sourceText\": \"Days 1 through 9\"}, {\"id\": \"rep_window_30\", \"type\": \"Continuous\", \"startOffset\": \"P31D\", \"endOffset\": \"P35D\", \"sourceText\": \"Days 31 through 35\"}, {\"id\": \"rep_window_32\", \"type\": \"Continuous\", \"startOffset\": \"P36D\", \"endOffset\": \"P39D\", \"sourceText\": \"Days 36 through 39\"}, {\"id\": \"rep_window_33\", \"type\": \"Continuous\", \"startOffset\": \"P9D\", \"endOffset\": \"P23D\", \"sourceText\": \"Day 9 to Day 23\"}, {\"id\": \"rep_window_34\", \"type\": \"Continuous\", \"sourceText\": \"Run-in Period\"}, {\"id\": \"rep_window_39\", \"type\": \"Continuous\", \"sourceText\": \"treatment period\"}, {\"id\": \"rep_window_40\", \"type\": \"Continuous\", \"sourceText\": \"Treatment Period\"}, {\"id\": \"rep_window_46\", \"type\": \"Continuous\", \"sourceText\": \"treatment \\nperiod\"}, {\"id\": \"rep_window_51\", \"type\": \"Continuous\", \"sourceText\": \"dosing period\"}, {\"id\": \"rep_window_52\", \"type\": \"Continuous\", \"sourceText\": \"pretreatment period\"}, {\"id\": \"rep_window_53\", \"type\": \"Continuous\", \"sourceText\": \"post-treatment period\"}, {\"id\": \"rep_window_54\", \"type\": \"Continuous\", \"sourceText\": \"2 hours after\"}, {\"id\": \"rep_window_56\", \"type\": \"Continuous\", \"sourceText\": \"8 hours before\"}, {\"id\": \"rep_window_57\", \"type\": \"Continuous\", \"sourceText\": \"4 hours post\"}, {\"id\": \"rep_window_58\", \"type\": \"Continuous\", \"sourceText\": \"21 days after\"}, {\"id\": \"rep_window_59\", \"type\": \"Continuous\", \"sourceText\": \"Inpatient Period\"}, {\"id\": \"rep_window_60\", \"type\": \"Continuous\", \"sourceText\": \"inpatient Period\"}, {\"id\": \"rep_window_62\", \"type\": \"Continuous\", \"sourceText\": \"Inpatient \\nPeriod\"}, {\"id\": \"rep_window_64\", \"type\": \"Continuous\", \"sourceText\": \"inpatient period\"}, {\"id\": \"rep_window_67\", \"type\": \"Continuous\", \"sourceText\": \"inpatient \\nperiod\"}, {\"id\": \"rep_window_70\", \"type\": \"Continuous\", \"sourceText\": \"balance period\"}, {\"id\": \"rep_window_71\", \"type\": \"Continuous\", \"sourceText\": \"24-hour urine\"}, {\"id\": \"rep_window_72\", \"type\": \"Continuous\", \"sourceText\": \"24-hour collection\"}, {\"id\": \"rep_daily_bound_1\", \"type\": \"Daily\", \"startOffset\": \"-P8D\", \"endOffset\": \"P9D\", \"interval\": \"P1D\", \"count\": 18, \"sourceText\": \"controlled diet (Day -8 to Day 9)\"}, {\"id\": \"rep_daily_bound_3\", \"type\": \"Daily\", \"startOffset\": \"P23D\", \"endOffset\": \"P40D\", \"interval\": \"P1D\", \"count\": 18, \"sourceText\": \"controlled diet (Day 23 to Day 40)\"}, {\"id\": \"rep_daily_bound_5\", \"type\": \"Daily\", \"startOffset\": \"-P7D\", \"endOffset\": \"-P5D\", \"interval\": \"P1D\", \"count\": 3, \"sourceText\": \"controlled diet (Day -7 through \\nDay -5)\"}, {\"id\": \"rep_daily_bound_6\", \"type\": \"Daily\", \"startOffset\": \"-P4D\", \"endOffset\": \"-P1D\", \"interval\": \"P1D\", \"count\": 4, \"sourceText\": \"controlled diet (Day -4 through Day -1)\"}, {\"id\": \"rep_daily_bound_11\", \"type\": \"Daily\", \"startOffset\": \"P3D\", \"endOffset\": \"P15D\", \"interval\": \"P1D\", \"count\": 13, \"sourceText\": \"controlled diet (3 to 15)\"}, {\"id\": \"rep_daily_bound_12\", \"type\": \"Daily\", \"startOffset\": \"P101D\", \"endOffset\": \"P201D\", \"interval\": \"P1D\", \"count\": 101, \"sourceText\": \"copper balance (101-201)\"}, {\"id\": \"rep_daily_bound_13\", \"type\": \"Daily\", \"startOffset\": \"-P4D\", \"endOffset\": \"-P1D\", \"interval\": \"P1D\", \"count\": 4, \"sourceText\": \"copper balance (Days -4 through -1)\"}, {\"id\": \"rep_daily_bound_14\", \"type\": \"Daily\", \"startOffset\": \"-P7D\", \"endOffset\": \"-P5D\", \"interval\": \"P1D\", \"count\": 3, \"sourceText\": \"molybdenum balance (Day -7 through Day -5)\"}, {\"id\": \"rep_daily_bound_15\", \"type\": \"Daily\", \"startOffset\": \"-P4D\", \"endOffset\": \"-P1D\", \"interval\": \"P1D\", \"count\": 4, \"sourceText\": \"molybdenum balance (Day -4 through Day -1)\"}, {\"id\": \"rep_daily_bound_17\", \"type\": \"Daily\", \"startOffset\": \"P1D\", \"endOffset\": \"P8D\", \"interval\": \"P1D\", \"count\": 8, \"sourceText\": \"molybdenum balance (Day 1 through Day 8)\"}, {\"id\": \"rep_daily_bound_18\", \"type\": \"Daily\", \"startOffset\": \"P25D\", \"endOffset\": \"P39D\", \"interval\": \"P1D\", \"count\": 15, \"sourceText\": \"molybdenum balance (Day 25 through Day 39)\"}, {\"id\": \"rep_daily_bound_22\", \"type\": \"Daily\", \"startOffset\": \"-P7D\", \"endOffset\": \"-P5D\", \"interval\": \"P1D\", \"count\": 3, \"sourceText\": \"molybdenum balance (Day -7 through \\nDay -5)\"}, {\"id\": \"rep_daily_bound_24\", \"type\": \"Daily\", \"startOffset\": \"-P8D\", \"endOffset\": \"P9D\", \"interval\": \"P1D\", \"count\": 18, \"sourceText\": \"molybdenum balance (Day -8 to Day 9)\"}, {\"id\": \"rep_daily_bound_25\", \"type\": \"Daily\", \"startOffset\": \"P23D\", \"endOffset\": \"P40D\", \"interval\": \"P1D\", \"count\": 18, \"sourceText\": \"molybdenum balance (Day 23 to Day 40)\"}, {\"id\": \"rep_daily_bound_29\", \"type\": \"Daily\", \"startOffset\": \"P3D\", \"endOffset\": \"P15D\", \"interval\": \"P1D\", \"count\": 13, \"sourceText\": \"copper balance (3 to 15)\"}, {\"id\": \"rep_daily_bound_30\", \"type\": \"Daily\", \"startOffset\": \"P3D\", \"endOffset\": \"P15D\", \"interval\": \"P1D\", \"count\": 13, \"sourceText\": \"molybdenum balance (3 to 15)\"}, {\"id\": \"rep_daily_bound_31\", \"type\": \"Daily\", \"startOffset\": \"P101D\", \"endOffset\": \"P301D\", \"interval\": \"P1D\", \"count\": 201, \"sourceText\": \"molybdenum balance (101-301)\"}, {\"id\": \"rep_daily_bound_32\", \"type\": \"Daily\", \"startOffset\": \"P3D\", \"endOffset\": \"P5D\", \"interval\": \"P1D\", \"count\": 3, \"sourceText\": \"copper \\nbalance (3 - 5)\"}]"
              },
              {
                "id": "ac0bd1f6-36b8-4c81-9e4f-726d8eeb9091",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-traversalConstraints",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"traversal_1\", \"requiredSequence\": [], \"allowEarlyExit\": true, \"exitEpochIds\": [\"epoch_early_termination\"], \"mandatoryVisits\": [], \"sourceText\": \"[{'condition': 'Subject is at a US site designated to only perform screening procedures', 'path': ['SCREENING_PROCEDURES_ONLY']}, {'condition': 'Subject discontinues study intervention or withdraws from the study', 'path': ['EARLY_TERMINATION']}]\"}]"
              },
              {
                "id": "8fd7a84f-4dcf-4880-bd55-63bda3b9ca9b",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-footnoteConditions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"fn_cond_1\", \"conditionType\": \"general\", \"text\": \", and any \\napplicable local regulations\", \"footnoteId\": \"(b)\", \"structuredCondition\": \"compliance.local_regulations == 'applicable'\", \"appliesToActivityIds\": [], \"sourceText\": \", and any \\napplicable local regulations\"}, {\"id\": \"fn_cond_2\", \"conditionType\": \"general\", \"text\": \"and/or Alexion, may place participants at undue risk, in which \\ncase, participants may remain on the\", \"footnoteId\": \"(s)\", \"structuredCondition\": \"if(risk.participant == 'undue', then participant.status = 'may_remain_on_treatment')\", \"appliesToActivityIds\": [], \"sourceText\": \"and/or Alexion, may place participants at undue risk, in which \\ncase, participants may remain on the\"}, {\"id\": \"fn_cond_3\", \"conditionType\": \"general\", \"text\": \"Overall Rationale for the Amendment \\nThe main reason for preparation of this amendment was to clarify study procedures occurring \\nacross different sites in the US, so as to facilitate participant recruitment across different regions \\nof the US, and to lessen inconvenience for participants without compromising the quality of the \\nstudy\", \"footnoteId\": \"s.\", \"structuredCondition\": \"study.amendment.rationale == 'clarify_procedures_and_facilitate_recruitment'\", \"appliesToActivityIds\": [], \"sourceText\": \"Overall Rationale for the Amendment \\nThe main reason for preparation of this amendment was to clarif\"}, {\"id\": \"fn_cond_4\", \"conditionType\": \"general\", \"text\": \"To align the number of days \\nwith the mention of zinc \\ndiscontinuation elsewhere in the \\nprotocol\", \"footnoteId\": \"c.\", \"structuredCondition\": \"protocol.alignment.rationale == 'align_zinc_discontinuation_days'\", \"appliesToActivityIds\": [], \"sourceText\": \"To align the number of days \\nwith the mention of zinc \\ndiscontinuation elsewhere in the \\nprotocol\"}, {\"id\": \"fn_cond_5\", \"conditionType\": \"general\", \"text\": \"Overall Design \\nThis is a single-arm, open-label, repeat-dose study to evaluate the effects of ALXN\", \"footnoteId\": \"s.\", \"sourceText\": \"Overall Design \\nThis is a single-arm, open-label, repeat-dose study to evaluate the effects of ALXN\"}, {\"id\": \"fn_cond_6\", \"conditionType\": \"general\", \"text\": \"Disclosure Statement: This is an open-label,\", \"footnoteId\": \"e.\", \"sourceText\": \"Disclosure Statement: This is an open-label,\"}, {\"id\": \"fn_cond_7\", \"conditionType\": \"general\", \"text\": \"Number of Participants: \\nThe sample size will be approximately\", \"footnoteId\": \"m.\", \"sourceText\": \"Number of Participants: \\nThe sample size will be approximately\"}, {\"id\": \"fn_cond_8\", \"conditionType\": \"general\", \"text\": \"Intervention Groups and Duration: \\nTreatment-experienced\", \"footnoteId\": \"r.\", \"structuredCondition\": \"participant.history.treatment == 'experienced'\", \"appliesToActivityIds\": [], \"sourceText\": \"Intervention Groups and Duration: \\nTreatment-experienced\"}, {\"id\": \"fn_cond_9\", \"conditionType\": \"timing_after\", \"text\": \"Following screening and enrollment, \\nparticipants will have a Run-in Period to support diet equilibration\", \"footnoteId\": \"y.\", \"structuredCondition\": \"sequence(['Screening and Enrollment', 'Run-in Period'])\", \"appliesToActivityIds\": [], \"sourceText\": \"Following screening and enrollment, \\nparticipants will have a Run-in Period to support diet equilibr\"}, {\"id\": \"fn_cond_10\", \"conditionType\": \"general\", \"text\": \"Participants will have intake and output collection periods from Day -\", \"footnoteId\": \"t.\", \"structuredCondition\": \"timing.start('Intake and Output Collection') >= 'Day -X'\", \"appliesToActivityIds\": [], \"sourceText\": \"Participants will have intake and output collection periods from Day -\"}, {\"id\": \"fn_cond_11\", \"conditionType\": \"general\", \"text\": \"Participants may be discharged from the clinical research unit\", \"footnoteId\": \"e.\", \"sourceText\": \"Participants may be discharged from the clinical research unit\"}, {\"id\": \"fn_cond_12\", \"conditionType\": \"frequency_daily\", \"text\": \"In this situation, participants will be given additional investigational product to support \\ndaily dosing throughout the Outpatient Period\", \"footnoteId\": \"l.\", \"sourceText\": \"In this situation, participants will be given additional investigational product to support \\ndaily d\"}, {\"id\": \"fn_cond_13\", \"conditionType\": \"general\", \"text\": \"Race and ethnicity will be collected where permitted by local regulations\", \"footnoteId\": \"x.\", \"sourceText\": \"Race and ethnicity will be collected where permitted by local regulations\"}, {\"id\": \"fn_cond_14\", \"conditionType\": \"general\", \"text\": \"k A full physical examination will be performed at Screening, at check-in for the study, and at the End of the study/Early Termination Visit\", \"footnoteId\": \"d.\", \"sourceText\": \"k A full physical examination will be performed at Screening, at check-in for the study, and at the \"}, {\"id\": \"fn_cond_15\", \"conditionType\": \"general\", \"text\": \"Otherwise, a symptom-driven physical \\nexamination may be performed at other times, at the Principal Investigator’s discretion\", \"footnoteId\": \"t.\", \"sourceText\": \"Otherwise, a symptom-driven physical \\nexamination may be performed at other times, at the Principal \"}, {\"id\": \"fn_cond_16\", \"conditionType\": \"timing_after\", \"text\": \"m While in the CRU, study intervention will be administered after an overnight fast\", \"footnoteId\": \"y.\", \"sourceText\": \"m While in the CRU, study intervention will be administered after an overnight fast\"}, {\"id\": \"fn_cond_17\", \"conditionType\": \"general\", \"text\": \"As an outpatient, participants are expected to take \\nALXN\", \"footnoteId\": \"g.\", \"sourceText\": \"As an outpatient, participants are expected to take \\nALXN\"}, {\"id\": \"fn_cond_18\", \"conditionType\": \"general\", \"text\": \"n During the outpatient period, participants will use SMS text messaging to confirm study intervention administration\", \"footnoteId\": \"g.\", \"sourceText\": \"n During the outpatient period, participants will use SMS text messaging to confirm study interventi\"}, {\"id\": \"fn_cond_19\", \"conditionType\": \"general\", \"text\": \"In case of rechecks, and postdose serum \\nchemistry, participants may not have fasted for\", \"footnoteId\": \"n.\", \"sourceText\": \"In case of rechecks, and postdose serum \\nchemistry, participants may not have fasted for\"}, {\"id\": \"fn_cond_20\", \"conditionType\": \"general\", \"text\": \"r Laboratory assessment including chemistry, hematology, and coagulation parameters should be performed on Days -\", \"footnoteId\": \"n.\", \"sourceText\": \"r Laboratory assessment including chemistry, hematology, and coagulation parameters should be perfor\"}, {\"id\": \"fn_cond_21\", \"conditionType\": \"timing_after\", \"text\": \"s Menstruation check is for women only; women of childbearing potential should only be enrolled after a negative serum pregnancy test result at Screening\", \"footnoteId\": \"y.\", \"sourceText\": \"s Menstruation check is for women only; women of childbearing potential should only be enrolled afte\"}, {\"id\": \"fn_cond_22\", \"conditionType\": \"general\", \"text\": \"u Vital signs measurements and ECGs should be performed predose, unless otherwise specified\", \"footnoteId\": \"t.\", \"sourceText\": \"u Vital signs measurements and ECGs should be performed predose, unless otherwise specified\"}, {\"id\": \"fn_cond_23\", \"conditionType\": \"timing_after\", \"text\": \"v Copper- and molybdenum-controlled diet will be initiated after registration/inclusion\", \"footnoteId\": \"e.\", \"sourceText\": \"v Copper- and molybdenum-controlled diet will be initiated after registration/inclusion\"}, {\"id\": \"fn_cond_24\", \"conditionType\": \"general\", \"text\": \"While not in the CRU, participants will be encouraged to adhere to their usual copper-controlled diet\", \"footnoteId\": \"s.\", \"sourceText\": \"While not in the CRU, participants will be encouraged to adhere to their usual copper-controlled die\"}, {\"id\": \"fn_cond_25\", \"conditionType\": \"general\", \"text\": \"x For fecal samples, each individual sample will be independently collected with record of date, time, and weight of the sample\", \"footnoteId\": \"m.\", \"sourceText\": \"x For fecal samples, each individual sample will be independently collected with record of date, tim\"}, {\"id\": \"fn_cond_26\", \"conditionType\": \"timing_after\", \"text\": \"When multiple procedures are scheduled to occur at the \\nsame time, the following order of events should be strictly adhered to whenever possible: ECG, vital signs, blood \\nsampling\", \"footnoteId\": \"e.\", \"sourceText\": \"When multiple procedures are scheduled to occur at the \\nsame time, the following order of events sho\"}, {\"id\": \"fn_cond_27\", \"conditionType\": \"general\", \"text\": \"Given the robust improvement in copper \\ncontrol, it is hypothesized that doses within the\", \"footnoteId\": \"l.\", \"sourceText\": \"Given the robust improvement in copper \\ncontrol, it is hypothesized that doses within the\"}, {\"id\": \"fn_cond_28\", \"conditionType\": \"general\", \"text\": \"The current study will explore copper balance in response to \\ntreatment with ALXN\", \"footnoteId\": \"e.\", \"sourceText\": \"The current study will explore copper balance in response to \\ntreatment with ALXN\"}, {\"id\": \"fn_cond_29\", \"conditionType\": \"general\", \"text\": \"Copper balance will be assessed for the\", \"footnoteId\": \"e.\", \"sourceText\": \"Copper balance will be assessed for the\"}, {\"id\": \"fn_cond_30\", \"conditionType\": \"general\", \"text\": \"Further dose \\nadjustments will be made as appropriate\", \"footnoteId\": \"y.\", \"sourceText\": \"Further dose \\nadjustments will be made as appropriate\"}, {\"id\": \"fn_cond_31\", \"conditionType\": \"general\", \"text\": \"Deviation from the dose modification guidelines must be agreed with the Alexion Medical \\nMonitor\", \"footnoteId\": \"t.\", \"sourceText\": \"Deviation from the dose modification guidelines must be agreed with the Alexion Medical \\nMonitor\"}, {\"id\": \"fn_cond_32\", \"conditionType\": \"general\", \"text\": \"Over-the-counter medications may be given if they \\nare not expected to impact the outcome of the study\", \"footnoteId\": \"r.\", \"sourceText\": \"Over-the-counter medications may be given if they \\nare not expected to impact the outcome of the stu\"}, {\"id\": \"fn_cond_33\", \"conditionType\": \"general\", \"text\": \"Herbal remedies must be discontinued at least\", \"footnoteId\": \"y.\", \"sourceText\": \"Herbal remedies must be discontinued at least\"}, {\"id\": \"fn_cond_34\", \"conditionType\": \"general\", \"text\": \"St John’s wort \\nAny herbal remedy or dietary supplement containing \\nSt John’s wort\", \"footnoteId\": \"t.\", \"sourceText\": \"St John’s wort \\nAny herbal remedy or dietary supplement containing \\nSt John’s wort\"}, {\"id\": \"fn_cond_35\", \"conditionType\": \"timing_after\", \"text\": \"After EOS Visit\", \"footnoteId\": \"d.\", \"sourceText\": \"After EOS Visit\"}, {\"id\": \"fn_cond_36\", \"conditionType\": \"general\", \"text\": \"Contraception \\nParticipants must consistently and correctly use one or \\nmore of the appropriate contraceptive methods \\ndescribed in Section\", \"footnoteId\": \"t.\", \"sourceText\": \"Contraception \\nParticipants must consistently and correctly use one or \\nmore of the appropriate cont\"}, {\"id\": \"fn_cond_37\", \"conditionType\": \"general\", \"text\": \"A minimal set of screen failure information is \\nrequired to ensure transparent reporting of screen failure participants to meet the Consolidated \\nStandards of Reporting Trials\", \"footnoteId\": \"n.\", \"sourceText\": \"A minimal set of screen failure information is \\nrequired to ensure transparent reporting of screen f\"}, {\"id\": \"fn_cond_38\", \"conditionType\": \"general\", \"text\": \"Minimal information includes demography, screen failure details\", \"footnoteId\": \"s.\", \"sourceText\": \"Minimal information includes demography, screen failure details\"}, {\"id\": \"fn_cond_39\", \"conditionType\": \"general\", \"text\": \"Individuals who do not meet the criteria for participation in this study\", \"footnoteId\": \"d.\", \"sourceText\": \"Individuals who do not meet the criteria for participation in this study\"}, {\"id\": \"fn_cond_40\", \"conditionType\": \"general\", \"text\": \"Rescreened participants are not \\nrequired to reconsent as long as they have signed the latest version of the ICF\", \"footnoteId\": \"r.\", \"sourceText\": \"Rescreened participants are not \\nrequired to reconsent as long as they have signed the latest versio\"}, {\"id\": \"fn_cond_41\", \"conditionType\": \"general\", \"text\": \"If the study intervention is definitively discontinued, the \\nparticipant should remain in the study to be evaluated for safety follow-up\", \"footnoteId\": \"n.\", \"sourceText\": \"If the study intervention is definitively discontinued, the \\nparticipant should remain in the study \"}, {\"id\": \"fn_cond_42\", \"conditionType\": \"general\", \"text\": \"Discontinuation of study intervention for abnormal liver function should be considered by the \\nInvestigator when a participant meets one of the conditions outlined in the Dose Modification \\ncriteria\", \"footnoteId\": \"d.\", \"sourceText\": \"Discontinuation of study intervention for abnormal liver function should be considered by the \\nInves\"}, {\"id\": \"fn_cond_43\", \"conditionType\": \"general\", \"text\": \"If a clinically significant finding is identified\", \"footnoteId\": \"t.\", \"sourceText\": \"If a clinically significant finding is identified\"}, {\"id\": \"fn_cond_44\", \"conditionType\": \"general\", \"text\": \"This review of the ECG printed at the time of collection must \\nbe documented\", \"footnoteId\": \"d.\", \"sourceText\": \"This review of the ECG printed at the time of collection must \\nbe documented\"}, {\"id\": \"fn_cond_45\", \"conditionType\": \"timing_after\", \"text\": \"Participants must be considered for discontinuation from study intervention if any of the \\nfollowing occur during the study: \\n• Serious hypersensitivity reaction; \\n• Severe uncontrolled infection; \\n• Use of disallowed medication; \\n• Pregnancy or planned pregnancy\", \"footnoteId\": \"E.\", \"sourceText\": \"Participants must be considered for discontinuation from study intervention if any of the \\nfollowing\"}, {\"id\": \"fn_cond_46\", \"conditionType\": \"general\", \"text\": \"The study staff should \\nnotify Alexion and their site monitor of all study withdrawals as soon as possible\", \"footnoteId\": \"s.\", \"sourceText\": \"The study staff should \\nnotify Alexion and their site monitor of all study withdrawals as soon as po\"}, {\"id\": \"fn_cond_47\", \"conditionType\": \"general\", \"text\": \"• A participant may withdraw from the study at any time at his/her own request, or may \\nbe withdrawn at any time at the discretion of the Investigator for safety, behavioral, \\ncompliance, or administrative reasons\", \"footnoteId\": \"F.\", \"sourceText\": \"• A participant may withdraw from the study at any time at his/her own request, or may \\nbe withdrawn\"}, {\"id\": \"fn_cond_48\", \"conditionType\": \"general\", \"text\": \"• Immediate safety concerns should be discussed with Alexion immediately upon \\noccurrence or awareness to determine if the participant should continue or \\ndiscontinue study intervention\", \"footnoteId\": \"d.\", \"sourceText\": \"• Immediate safety concerns should be discussed with Alexion immediately upon \\noccurrence or awarene\"}, {\"id\": \"fn_cond_49\", \"conditionType\": \"general\", \"text\": \"• All screening evaluations must be completed and reviewed to confirm that potential \\nparticipants meet all eligibility criteria\", \"footnoteId\": \"t.\", \"sourceText\": \"• All screening evaluations must be completed and reviewed to confirm that potential \\nparticipants m\"}, {\"id\": \"fn_cond_50\", \"conditionType\": \"timing_after\", \"text\": \"• The following only applies to sites in the US\", \"footnoteId\": \"e.\", \"sourceText\": \"• The following only applies to sites in the US\"}, {\"id\": \"fn_cond_51\", \"conditionType\": \"general\", \"text\": \"Some sites may perform screening procedures only and \\nnot any of the remaining study procedures\", \"footnoteId\": \"e.\", \"sourceText\": \"Some sites may perform screening procedures only and \\nnot any of the remaining study procedures\"}, {\"id\": \"fn_cond_52\", \"conditionType\": \"general\", \"text\": \"Site-to-site transfer of the participant will be documented \\naccordingly\", \"footnoteId\": \"r.\", \"sourceText\": \"Site-to-site transfer of the participant will be documented \\naccordingly\"}, {\"id\": \"fn_cond_53\", \"conditionType\": \"general\", \"text\": \"The copper and molybdenum concentration of each sample will be determined by inductively \\ncoupled plasma mass spectrometry\", \"footnoteId\": \"A.\", \"sourceText\": \"The copper and molybdenum concentration of each sample will be determined by inductively \\ncoupled pl\"}, {\"id\": \"fn_cond_54\", \"conditionType\": \"general\", \"text\": \"All participants will drink water from the same large water bottle \\ndispenser\", \"footnoteId\": \"s.\", \"sourceText\": \"All participants will drink water from the same large water bottle \\ndispenser\"}, {\"id\": \"fn_cond_55\", \"conditionType\": \"general\", \"text\": \"Samples will be collected, stored and shipped as detailed in the Laboratory Manual\", \"footnoteId\": \"t.\", \"sourceText\": \"Samples will be collected, stored and shipped as detailed in the Laboratory Manual\"}, {\"id\": \"fn_cond_56\", \"conditionType\": \"general\", \"text\": \"All sample handling procedures will be documented in detail as \\ndescribed in the Laboratory Manual\", \"footnoteId\": \"d.\", \"sourceText\": \"All sample handling procedures will be documented in detail as \\ndescribed in the Laboratory Manual\"}, {\"id\": \"fn_cond_57\", \"conditionType\": \"general\", \"text\": \"Fecal samples will be individually collected, weighed, and stored\", \"footnoteId\": \"l.\", \"sourceText\": \"Fecal samples will be individually collected, weighed, and stored\"}, {\"id\": \"fn_cond_58\", \"conditionType\": \"general\", \"text\": \"Pharmacokinetic collection should occur as close as possible to the scheduled time\", \"footnoteId\": \"l.\", \"sourceText\": \"Pharmacokinetic collection should occur as close as possible to the scheduled time\"}, {\"id\": \"fn_cond_59\", \"conditionType\": \"general\", \"text\": \"• Blood pressure and heart rate measurements will be assessed with a completely \\nautomated device\", \"footnoteId\": \"y.\", \"sourceText\": \"• Blood pressure and heart rate measurements will be assessed with a completely \\nautomated device\"}, {\"id\": \"fn_cond_60\", \"conditionType\": \"general\", \"text\": \"• Vital signs will be measured in a supine position after\", \"footnoteId\": \"s.\", \"sourceText\": \"• Vital signs will be measured in a supine position after\"}, {\"id\": \"fn_cond_61\", \"conditionType\": \"general\", \"text\": \"Vital signs will consist \\nof a single pulse and blood pressure measurement\", \"footnoteId\": \"e.\", \"sourceText\": \"Vital signs will consist \\nof a single pulse and blood pressure measurement\"}, {\"id\": \"fn_cond_62\", \"conditionType\": \"general\", \"text\": \"The average of the blood pressure readings will be \\nrecorded in the CRF\", \"footnoteId\": \"y.\", \"sourceText\": \"The average of the blood pressure readings will be \\nrecorded in the CRF\"}, {\"id\": \"fn_cond_63\", \"conditionType\": \"general\", \"text\": \"As with vital \\nsigns, if ECG interval measurements are abnormal, an additional triplicate will be \\nperformed and recorded in the CRF\", \"footnoteId\": \"y.\", \"sourceText\": \"As with vital \\nsigns, if ECG interval measurements are abnormal, an additional triplicate will be \\np\"}, {\"id\": \"fn_cond_64\", \"conditionType\": \"general\", \"text\": \"• The Investigator must review the laboratory report, document this review, and record any \\nclinically relevant changes occurring during the study in the AE section of the CRF\", \"footnoteId\": \"y.\", \"sourceText\": \"• The Investigator must review the laboratory report, document this review, and record any \\nclinical\"}, {\"id\": \"fn_cond_65\", \"conditionType\": \"general\", \"text\": \"Clinically significant \\nlaboratory values are those deemed by the Investigator to be clinically significant \\nresulting in further evaluation or treatment or those associated with an AE or clinical \\nsigns or symptoms\", \"footnoteId\": \"s.\", \"sourceText\": \"Clinically significant \\nlaboratory values are those deemed by the Investigator to be clinically sign\"}, {\"id\": \"fn_cond_66\", \"conditionType\": \"general\", \"text\": \"− If such values do not return to normal/baseline within a period of time judged \\nreasonable by the Investigator, the etiology should be identified, and Alexion \\nnotified\", \"footnoteId\": \"r.\", \"sourceText\": \"− If such values do not return to normal/baseline within a period of time judged \\nreasonable by the \"}, {\"id\": \"fn_cond_67\", \"conditionType\": \"general\", \"text\": \"− All laboratory values from non-protocol-specified laboratory assessments must \\nalso be recorded in the CRF\", \"footnoteId\": \"A.\", \"sourceText\": \"− All laboratory values from non-protocol-specified laboratory assessments must \\nalso be recorded in\"}, {\"id\": \"fn_cond_68\", \"conditionType\": \"general\", \"text\": \"• Total molybdenum and PUF-molybdenum are surrogate measures of ALXN\", \"footnoteId\": \"d.\", \"sourceText\": \"• Total molybdenum and PUF-molybdenum are surrogate measures of ALXN\"}, {\"id\": \"fn_cond_69\", \"conditionType\": \"general\", \"text\": \"• Excess/additional samples may be stored for up to\", \"footnoteId\": \"y.\", \"sourceText\": \"• Excess/additional samples may be stored for up to\"}, {\"id\": \"fn_cond_70\", \"conditionType\": \"general\", \"text\": \"Blood samples will be collected as described in the SoA\", \"footnoteId\": \"y.\", \"sourceText\": \"Blood samples will be collected as described in the SoA\"}, {\"id\": \"fn_cond_71\", \"conditionType\": \"procedure_conditional\", \"text\": \"Plasma samples will be used for ICP-MS measurement of total copper and \\nPUF-copper, ceruloplasmin, ceruloplasmin-bound copper, and non-ceruloplasmin-bound copper \\nmeasured via PUF-copper, and/or LBC, or assessed via NCC/NCCcorrected methods at the time \\npoints indicated in the SoA\", \"footnoteId\": \"l.\", \"sourceText\": \"Plasma samples will be used for ICP-MS measurement of total copper and \\nPUF-copper, ceruloplasmin, c\"}, {\"id\": \"fn_cond_72\", \"conditionType\": \"general\", \"text\": \"Benefit-Risk Assessment\", \"footnoteId\": \"3.\", \"sourceText\": \"Benefit-Risk Assessment\"}, {\"id\": \"fn_cond_73\", \"conditionType\": \"general\", \"text\": \"Benefit Assessment\", \"footnoteId\": \"2.\", \"sourceText\": \"Benefit Assessment\"}, {\"id\": \"fn_cond_74\", \"conditionType\": \"general\", \"text\": \"Scientific Rationale for Study Design\", \"footnoteId\": \"2.\", \"sourceText\": \"Scientific Rationale for Study Design\"}, {\"id\": \"fn_cond_75\", \"conditionType\": \"general\", \"text\": \"Justification for Dose\", \"footnoteId\": \"3.\", \"sourceText\": \"Justification for Dose\"}, {\"id\": \"fn_cond_76\", \"conditionType\": \"general\", \"text\": \"Lifestyle Considerations\", \"footnoteId\": \"3.\", \"sourceText\": \"Lifestyle Considerations\"}, {\"id\": \"fn_cond_77\", \"conditionType\": \"general\", \"text\": \"Adverse Events: Definitions and Procedures for Recording, Evaluating, \\nFollow-up, and Reporting\", \"footnoteId\": \"3.\", \"sourceText\": \"Adverse Events: Definitions and Procedures for Recording, Evaluating, \\nFollow-up, and Reporting\"}, {\"id\": \"fn_cond_78\", \"conditionType\": \"general\", \"text\": \"Recording and Follow-Up of AE and/or SAE\", \"footnoteId\": \"3.\", \"sourceText\": \"Recording and Follow-Up of AE and/or SAE\"}, {\"id\": \"fn_cond_79\", \"conditionType\": \"general\", \"text\": \"Contraceptive Guidance and Collection of Pregnancy Information\", \"footnoteId\": \"4.\", \"sourceText\": \"Contraceptive Guidance and Collection of Pregnancy Information\"}, {\"id\": \"fn_cond_80\", \"conditionType\": \"general\", \"text\": \"Note: “Enrolled” means all participants who sign the informed consent form\", \"footnoteId\": \"1840.\", \"sourceText\": \"Note: “Enrolled” means all participants who sign the informed consent form\"}, {\"id\": \"fn_cond_81\", \"conditionType\": \"timing_before\", \"text\": \"Before titration to\", \"footnoteId\": \"29.\", \"sourceText\": \"Before titration to\"}, {\"id\": \"fn_cond_82\", \"conditionType\": \"general\", \"text\": \"The \\ncollection periods will support an assessment of both copper and molybdenum balance\", \"footnoteId\": \"39.\", \"sourceText\": \"The \\ncollection periods will support an assessment of both copper and molybdenum balance\"}, {\"id\": \"fn_cond_83\", \"conditionType\": \"frequency_continuous\", \"text\": \"To ensure flexibility, the Outpatient \\nPeriod during Treatment Period\", \"footnoteId\": \"23.\", \"sourceText\": \"To ensure flexibility, the Outpatient \\nPeriod during Treatment Period\"}, {\"id\": \"fn_cond_84\", \"conditionType\": \"general\", \"text\": \"p PK/PD collection will include timepoints described in the schedule of PK/PD assessment for Days\", \"footnoteId\": \"39.\", \"sourceText\": \"p PK/PD collection will include timepoints described in the schedule of PK/PD assessment for Days\"}, {\"id\": \"fn_cond_85\", \"conditionType\": \"general\", \"text\": \"Abbreviations: Cu = copper; LBC = labile bound copper; Mo = molybdenum; PD = pharmacodynamic; \\nPK = pharmacokinetic; PUF = plasma ultrafiltrate\", \"footnoteId\": \"1840.\", \"sourceText\": \"Abbreviations: Cu = copper; LBC = labile bound copper; Mo = molybdenum; PD = pharmacodynamic; \\nPK = \"}, {\"id\": \"fn_cond_86\", \"conditionType\": \"general\", \"text\": \"The multiple collection periods will support assessment of duration of treatment and dose on \\ncopper elimination and overall copper balance\", \"footnoteId\": \"39.\", \"sourceText\": \"The multiple collection periods will support assessment of duration of treatment and dose on \\ncopper\"}, {\"id\": \"fn_cond_87\", \"conditionType\": \"general\", \"text\": \"End of Study Definition \\nA participant is considered to have completed the study if he/she has completed all phases of the \\nstudy including the last scheduled procedure shown in the Schedule of Activities\", \"footnoteId\": \"4.\", \"sourceText\": \"End of Study Definition \\nA participant is considered to have completed the study if he/she has compl\"}, {\"id\": \"fn_cond_88\", \"conditionType\": \"general\", \"text\": \"Start times for \\ncontraceptives vary \\naccording to method used\", \"footnoteId\": \"4.\", \"sourceText\": \"Start times for \\ncontraceptives vary \\naccording to method used\"}, {\"id\": \"fn_cond_89\", \"conditionType\": \"general\", \"text\": \"Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of \\nActivities\", \"footnoteId\": \"4.\", \"sourceText\": \"Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Sched\"}, {\"id\": \"fn_cond_90\", \"conditionType\": \"general\", \"text\": \"Screen Failures  \\nScreen failures are defined as participants who consent to participate in the clinical study but are \\nnot subsequently assigned to study intervention\", \"footnoteId\": \"4.\", \"sourceText\": \"Screen Failures  \\nScreen failures are defined as participants who consent to participate in the clin\"}, {\"id\": \"fn_cond_91\", \"conditionType\": \"general\", \"text\": \"Discontinuation of Study Intervention \\nIn rare instances, it may be necessary for a participant to permanently discontinue\", \"footnoteId\": \"1.\", \"sourceText\": \"Discontinuation of Study Intervention \\nIn rare instances, it may be necessary for a participant to p\"}, {\"id\": \"fn_cond_92\", \"conditionType\": \"timing_before\", \"text\": \"Participant Discontinuation/Withdrawal From the Study \\n• All efforts should be made to ensure participants are willing to comply with study \\nparticipation prior to conducting the screening procedures\", \"footnoteId\": \"2.\", \"sourceText\": \"Participant Discontinuation/Withdrawal From the Study \\n• All efforts should be made to ensure partic\"}, {\"id\": \"fn_cond_93\", \"conditionType\": \"general\", \"text\": \"STUDY ASSESSMENTS AND PROCEDURES \\n• Study procedures and their timing are summarized in the SoA\", \"footnoteId\": \"8.\", \"sourceText\": \"STUDY ASSESSMENTS AND PROCEDURES \\n• Study procedures and their timing are summarized in the SoA\"}, {\"id\": \"fn_cond_94\", \"conditionType\": \"general\", \"text\": \"Efficacy Assessments\", \"footnoteId\": \"1.\", \"sourceText\": \"Efficacy Assessments\"}, {\"id\": \"fn_cond_95\", \"conditionType\": \"general\", \"text\": \"Copper and Molybdenum Balance Measurements \\nCopper and molybdenum balance measurements will be made on all intake\", \"footnoteId\": \"1.\", \"sourceText\": \"Copper and Molybdenum Balance Measurements \\nCopper and molybdenum balance measurements will be made \"}, {\"id\": \"fn_cond_96\", \"conditionType\": \"general\", \"text\": \"Food and Fluid Collection for Copper and Molybdenum Concentrations \\nSamples of all meal and fluid batches will be collected and analyzed for measurement of copper \\nand molybdenum content\", \"footnoteId\": \"1.\", \"sourceText\": \"Food and Fluid Collection for Copper and Molybdenum Concentrations \\nSamples of all meal and fluid ba\"}, {\"id\": \"fn_cond_97\", \"conditionType\": \"general\", \"text\": \"Urine Collection for Measurement of Copper and Molybdenum content \\nUrine samples to measure copper and molybdenum content will be collected periodically as \\ndescribed in the SoA\", \"footnoteId\": \"2.\", \"sourceText\": \"Urine Collection for Measurement of Copper and Molybdenum content \\nUrine samples to measure copper a\"}, {\"id\": \"fn_cond_98\", \"conditionType\": \"general\", \"text\": \"Safety Assessments \\nPlanned time points for all safety assessments are provided in the SoA\", \"footnoteId\": \"2.\", \"sourceText\": \"Safety Assessments \\nPlanned time points for all safety assessments are provided in the SoA\"}, {\"id\": \"fn_cond_99\", \"conditionType\": \"general\", \"text\": \"Physical Examinations \\n• A complete physical examination will include, at a minimum, assessments of the \\ncardiovascular, respiratory, gastrointestinal, and neurological systems\", \"footnoteId\": \"1.\", \"sourceText\": \"Physical Examinations \\n• A complete physical examination will include, at a minimum, assessments of \"}, {\"id\": \"fn_cond_100\", \"conditionType\": \"general\", \"text\": \"Vital Signs \\n• Body temperature, heart rate, respiratory rate, and systolic and diastolic blood pressure\", \"footnoteId\": \"2.\", \"sourceText\": \"Vital Signs \\n• Body temperature, heart rate, respiratory rate, and systolic and diastolic blood pres\"}, {\"id\": \"fn_cond_101\", \"conditionType\": \"general\", \"text\": \"Electrocardiograms \\n• Triplicate\", \"footnoteId\": \"3.\", \"sourceText\": \"Electrocardiograms \\n• Triplicate\"}, {\"id\": \"fn_cond_102\", \"conditionType\": \"general\", \"text\": \"Clinical Safety Laboratory Assessments \\n• See Section\", \"footnoteId\": \"4.\", \"sourceText\": \"Clinical Safety Laboratory Assessments \\n• See Section\"}, {\"id\": \"fn_cond_103\", \"conditionType\": \"timing_after\", \"text\": \"Samples collected for \\nanalyses of plasma concentrations may also be used to evaluate safety aspects related \\nto concerns arising during or after the study\", \"footnoteId\": \"1840.\", \"sourceText\": \"Samples collected for \\nanalyses of plasma concentrations may also be used to evaluate safety aspects\"}, {\"id\": \"fn_cond_104\", \"conditionType\": \"general\", \"text\": \"These samples will not be \\nused for genetic analyses\", \"footnoteId\": \"1840.\", \"sourceText\": \"These samples will not be \\nused for genetic analyses\"}, {\"id\": \"fn_cond_105\", \"conditionType\": \"general\", \"text\": \"Pharmacodynamics \\nPlasma total and PUF-copper, ceruloplasmin, ceruloplasmin-bound copper, and LBC will be \\nassessed during the study\", \"footnoteId\": \"6.\", \"sourceText\": \"Pharmacodynamics \\nPlasma total and PUF-copper, ceruloplasmin, ceruloplasmin-bound copper, and LBC wi\"}, {\"id\": \"fn_cond_106\", \"conditionType\": \"general\", \"text\": \"Genetics \\nGenetics will not be evaluated in this study\", \"footnoteId\": \"7.\", \"sourceText\": \"Genetics \\nGenetics will not be evaluated in this study\"}, {\"id\": \"fn_cond_107\", \"conditionType\": \"general\", \"text\": \"Immunogenicity Assessments \\nNot applicable\", \"footnoteId\": \"9.\", \"sourceText\": \"Immunogenicity Assessments \\nNot applicable\"}, {\"id\": \"fn_cond_108\", \"conditionType\": \"general\", \"text\": \"Health Economics Data and/or Medical Resource Utilization \\nHealth economic and medical resource utilization parameters are not evaluated in this study\", \"footnoteId\": \"10.\", \"sourceText\": \"Health Economics Data and/or Medical Resource Utilization \\nHealth economic and medical resource util\"}]"
              },
              {
                "id": "29c13839-6cb9-4e5d-8853-107273ad56eb",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-endpointAlgorithms",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"ep_1\", \"name\": \"Exploratory Endpoint 1\", \"endpointType\": \"Exploratory\", \"inputs\": [\"OS\", \"PR\", \"CR\"], \"unit\": \"%\", \"sourceText\": \"--- Page 51 ---\\nProtocol Amendment 3.1 (US) \\n \\nALXN1840-WD-204 \\n18 Mar 2022 \\nPage 51 of 74 \\nAlexion Confidential \\n9. \\nSTATISTICAL CONSIDERATIONS \\n9.1. \\nStatistical Hypotheses \\n9.1.1. \\nPrimary Hypothes\"}, {\"id\": \"ep_2\", \"name\": \"analysis will be excluded from the Per \\nProtocol (PP) Set\", \"endpointType\": \"Primary\", \"inputs\": [\"PR\", \"CR\"], \"timeWindow\": {\"reference\": \"the per\", \"duration\": null}, \"algorithm\": \"informed consent form; pd = pharmacodynamic; pk = pharmacokinetic\", \"sourceText\": \"primary endpoint analysis will be excluded from the Per \\nProtocol (PP) Set. Major protocol deviations, and the PP Set, will be \\ndefined, documented, and agreed within Alexion prior to database lock. \\n\"}, {\"id\": \"ep_3\", \"name\": \"of this study is to demonstrate a net negative copper balance with daily \\nrepeat-dose ALXN1840 treat\", \"endpointType\": \"Primary\", \"inputs\": [\"OS\", \"PR\"], \"unit\": \"mg\", \"sourceText\": \"primary objective of this study is to demonstrate a net negative copper balance with daily \\nrepeat-dose ALXN1840 treatment (15 mg and 30 mg) in participants with WD. \\n\"}]"
              },
              {
                "id": "628ece83-2ca0-4dec-abf3-30de11501d74",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-derivedVariables",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"dv_1\", \"name\": \"will be\", \"variableType\": \"Custom\", \"sourceVariables\": [\"ALT\"], \"derivationRule\": \"the \\ndifference between measured copper input in food and drink and measured copper output in \\nurine and feces\", \"unit\": \"15\", \"sourceText\": \"--- Page 9 ---\\nProtocol Amendment 3.1 (US) \\n \\nALXN1840-WD-204 \\n18 Mar 2022 \\nPage 9 of 74 \\nAlexion Confidential \\n1. \\nPROTOCOL SUMMARY \\n1.1. \\nSynopsis \\nProtocol Title: A Phase 2, Open-label Study to Ass\"}, {\"id\": \"dv_6\", \"name\": \"Derived Variable 6\", \"variableType\": \"Custom\", \"sourceVariables\": [\"on copper\", \"pk parameters\", \"heart rate\", \"blood pressure\", \"5 times\"], \"baselineVisit\": \"day \\n39\", \"analysisWindow\": \"day \\n39\", \"unit\": \"15\", \"sourceText\": \"\\n• Vital sign assessments (blood pressure and heart rate) \\nExploratory \\nDetermine dose response of ALXN1840 15 mg/day \\nand 30 mg/day for copper balance in participants \\nwith WD \\nAssess dose response o\"}, {\"id\": \"dv_7\", \"name\": \"Derived Variable 7\", \"variableType\": \"Custom\", \"baselineVisit\": \"day -4\", \"sourceText\": \"\\n• \\nBaseline Day -4 through Day -1 \"}, {\"id\": \"dv_12\", \"name\": \"copper balance\", \"variableType\": \"ChangeFromBaseline\", \"sourceVariables\": [\"weight\", \"safety\", \"total molybdenum\", \"ALT\", \"a \\ntotal\"], \"derivationRule\": \"the difference between measured copper input in food and drink and measured \\ncopper output in urine and feces\", \"baselineVisit\": \"day 54\", \"analysisWindow\": \"day 54\", \"unit\": \"toxic\", \"sourceText\": \"\\n• \\nEnd of Study Visit Day 54 +/- 2 days  \\nAbbreviations: AP = accumulation period; CRU = clinical research unit; EOS = End of Study; I/O = input/output; \\nPD = pharmacodynamic; PK = pharmacokinetic; S\"}, {\"id\": \"dv_17\", \"name\": \"Derived Variable 17\", \"variableType\": \"Custom\", \"sourceVariables\": [\"on copper\", \"pk parameters\", \"heart rate\", \"blood pressure\", \"5 times\"], \"baselineVisit\": \"day 39\", \"analysisWindow\": \"day 39\", \"unit\": \"15\", \"sourceText\": \"\\n• Vital sign assessments (blood pressure and heart rate) \\nExploratory \\nDetermine dose response of ALXN1840 15 mg/day \\nand 30 mg/day for copper balance in participants \\nwith WD \\nAssess dose response o\"}, {\"id\": \"dv_19\", \"name\": \"will be\", \"variableType\": \"Baseline\", \"sourceVariables\": [\"full analysis\", \"world health\", \"pk\", \"AST\", \"noncompartmental methods\", \"descriptive statistics\", \"safety analysis\", \"heart rate\", \"ALT\", \"criteria established\", \"same methods\", \"fractional intake\", \"sas\", \"actual sampling\"], \"derivationRule\": \"the mean daily copper balance over each of the 4 \\ncollection periods\", \"baselineVisit\": \"day -8\", \"analysisWindow\": \"day 9\", \"unit\": \"15\", \"sourceText\": \"\\n• Cohort 2 (treatment naïve): Patients who have received WD therapy for ≤ 28 days \\nFollowing screening and enrollment, participants will check-in to the CRU on Day -8 for the \\nRun-in Period. The purp\"}, {\"id\": \"dv_26\", \"name\": \"Derived Variable 26\", \"variableType\": \"Custom\", \"sourceVariables\": [\"AST\"], \"baselineVisit\": \"day25\", \"analysisWindow\": \"day 28\", \"unit\": \"15\", \"sourceText\": \"\\n• Accumulation ratio (AR) calculated as: \\nFor 15 mg/day:  \\n− Cmax,Day25/Cmax,Day1 \\n− Ctrough,Day26/Ctrough,Day2 \\n− AUCtau,Day25/AUC tau,Day1  \\nFor 30 mg/day:  \\n− Cmax,Day39/Cmax,Day29,adjusted \\n− Ctr\"}, {\"id\": \"dv_30\", \"name\": \"may be\", \"variableType\": \"PercentChange\", \"sourceVariables\": [\"following \\ndescriptive\", \"any emerging\", \"fridericia\", \"heart rate\", \"ALT\", \"following descriptive\", \"BMI\"], \"derivationRule\": \"sae \\nserious adverse event  \\nsap \\nstatistical analysis plan  \\nsoa \\nschedule of activities \\nsrc \\nsafety review committee \\nsusar \\nsuspected unexpected serious adverse reaction \\nteae \\ntreatment-emergent adverse event  \\nt½ \\nterminal elimination half-life  \\ntlag \\ntime delay between the time of dosing and time of appearance of molybdenum \\nconcentration \\ntmax \\ntime to maximum concentration  \\ntpc \\ntripartite complex \\nttm \\ntetrathiomolybdate \\nuln \\nupper limit of normal \\nuwdrs \\nunified wilson disease rating scale \\nvd/f \\napparent volume of distribution  \\nwd \\nwilson disease  \\nwho \\nworld health organization\", \"unit\": \"15\", \"sourceText\": \"\\n• Apparent volume of distribution (Vd/F). \\nAdditional plasma PK parameters may be calculated if deemed appropriate. \\nPlasma concentrations of total molybdenum and PUF molybdenum vs. time data will be\"}]"
              },
              {
                "id": "e98664ff-dc56-4bb0-a92a-8a4779198c6d",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-stateMachine",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"sm_1\", \"initialState\": \"Screening\", \"terminalStates\": [\"Completed\", \"Discontinued\", \"Withdrawn\", \"Death\", \"LostToFollowUp\"], \"states\": [\"Screening\", \"OnTreatment\", \"Enrolled\", \"FollowUp\", \"Completed\", \"Discontinued\", \"Withdrawn\", \"Death\"], \"transitions\": [{\"fromState\": \"Screening\", \"toState\": \"OnTreatment\", \"trigger\": \"Progress from Screening to OnTreatment\"}, {\"fromState\": \"OnTreatment\", \"toState\": \"Enrolled\", \"trigger\": \"Progress from OnTreatment to Enrolled\"}, {\"fromState\": \"Enrolled\", \"toState\": \"OnTreatment\", \"trigger\": \"Progress from Enrolled to OnTreatment\"}, {\"fromState\": \"OnTreatment\", \"toState\": \"FollowUp\", \"trigger\": \"Progress from OnTreatment to FollowUp\"}, {\"fromState\": \"FollowUp\", \"toState\": \"Completed\", \"trigger\": \"Progress from FollowUp to Completed\"}, {\"fromState\": \"OnTreatment\", \"toState\": \"Discontinued\", \"trigger\": \"Discontinuation from treatment\"}]}"
              },
              {
                "id": "bef46924-c48d-4b64-8fe4-d46f703a4da2",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-dosingRegimens",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"dosing_1\", \"treatmentName\": \"for the\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"sourceText\": \"ry objective, to confirm that ALXN1840 steady state is adequately \\ncharacterized by the plasma pharmacokinetics (PK), a molybdenum mass balance assessment \\nwill be performed at predicted steady state \"}, {\"id\": \"dosing_2\", \"treatmentName\": \"day and\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 30.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"sourceText\": \"to confirm that ALXN1840 steady state is adequately \\ncharacterized by the plasma pharmacokinetics (PK), a molybdenum mass balance assessment \\nwill be performed at predicted steady state for the 15 mg/\"}, {\"id\": \"dosing_3\", \"treatmentName\": \"mg and\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 30.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"sourceText\": \" \\nALXN1840-WD-204 \\n18 Mar 2022 \\nPage 10 of 74 \\nAlexion Confidential \\nObjectives and Endpoints \\nObjectives \\nEndpoints \\nPrimary \\nAssess net copper balance with daily repeat-dose \\nALXN1840 treatment (15 \"}, {\"id\": \"dosing_4\", \"treatmentName\": \"to \\nALXN1840\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"sourceText\": \"copper \\nintake (in food and drink) and copper output (in feces and \\nurine) during ALXN1840 accumulation and steady-state \\nperiods for each dose \\nSecondary \\nAssess change in copper balance in response \"}, {\"id\": \"dosing_5\", \"treatmentName\": \"day \\nand\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 30.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"sourceText\": \") and copper output (in feces and urine) from \\npretreatment baseline (Days -4 through -1) and \\nALXN1840 accumulation and steady-state periods for \\neach dose \\nInvestigate the effect of ALXN1840 (15 mg/\"}, {\"id\": \"dosing_6\", \"treatmentName\": \"state at\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"sourceText\": \"luding plasma total and labile bound copper (LBC) \\nduring ALXN1840 accumulation and steady-state periods \\nfor each dose \\nInvestigate the effect of ALXN1840 on the \\ndisposition of molybdenum at steady \"}, {\"id\": \"dosing_7\", \"treatmentName\": \"of ALXN1840\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 0.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"sourceText\": \"0 mg/day in participants with WD \\nMolybdenum quantified in food, drink, feces, and urine, \\nplasma total molybdenum at ALXN1840 steady state \\nAssess steady-state total molybdenum balance as a \\nmeasure \"}, {\"id\": \"dosing_8\", \"treatmentName\": \"treatment at\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"sourceText\": \"through \\nmeasurement of molybdenum intake (in food, drink and \\nALXN1840), and molybdenum output (feces and urine) \\nrepresenting ALXN1840 steady state \\nAssess accumulation of molybdenum with \\nALXN1840 \"}, {\"id\": \"dosing_9\", \"treatmentName\": \"ALXN1840 at\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"durationDescription\": \"28 days\", \"sourceText\": \"port diet equilibration (Day -7 through Day -5) and \\nmeasurement of pretreatment copper and molybdenum balance (Day -4 through Day -1). \\nFollowing the Run-in Period, participants will be administered \"}, {\"id\": \"dosing_10\", \"treatmentName\": \"up to\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 30.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"durationDescription\": \"28 days\", \"sourceText\": \"olybdenum balance (Day -4 through Day -1). \\nFollowing the Run-in Period, participants will be administered ALXN1840 at 15 mg/day for a \\ntreatment period of approximately 28 days followed by titration \"}, {\"id\": \"dosing_11\", \"treatmentName\": \"titration to\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 30.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"durationDescription\": \"28 days\", \"sourceText\": \"ay -1). \\nFollowing the Run-in Period, participants will be administered ALXN1840 at 15 mg/day for a \\ntreatment period of approximately 28 days followed by titration up to 30 mg/day on Day 29. \\nBefore \"}, {\"id\": \"dosing_12\", \"treatmentName\": \"initial\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"sourceText\": \"ittee (SRC) will review available safety \\ndata through Day 23 for each participant. \\nParticipants will have intake and output collection periods from Day -4 through Day -1, from \\nDay 1 through Day 8 (\"}, {\"id\": \"dosing_13\", \"treatmentName\": \"at the\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"sourceText\": \"rough Day 8 (initial 15 mg/day collection period), and Day 25 through Day 39. The \\ncollection periods will support an assessment of both copper and molybdenum balance (as a \\nmeasure of ALXN1840 ADME) \"}, {\"id\": \"dosing_14\", \"treatmentName\": \"end of\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"sourceText\": \" conduct of the study.  \\nSafety Review Committee: \\nA Safety Review Committee (SRC), composed of a minimum of the Investigator, Alexion \\nMedical Monitor, and Alexion Safety Physician, will meet at the \"}, {\"id\": \"dosing_15\", \"treatmentName\": \"proceeding to\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 30.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"sourceText\": \"ew Committee: \\nA Safety Review Committee (SRC), composed of a minimum of the Investigator, Alexion \\nMedical Monitor, and Alexion Safety Physician, will meet at the end of 15 mg/day dosing to \\nconfirm \"}, {\"id\": \"dosing_16\", \"treatmentName\": \"dose of\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"sourceText\": \"ent Period. In such cases, the actual Outpatient Period duration will be \\nrecorded and the participant will continue Inpatient Period 2 at Day 23.  \\n3. Participants will be administered ALXN1840 at a \"}, {\"id\": \"dosing_17\", \"treatmentName\": \"increase to\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 30.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"sourceText\": \"iod duration will be \\nrecorded and the participant will continue Inpatient Period 2 at Day 23.  \\n3. Participants will be administered ALXN1840 at a dose of 15 mg/day on Day 1 through Day 28 and then \\n\"}, {\"id\": \"dosing_18\", \"treatmentName\": \"Interventionm \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nALXN1840\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"sourceText\": \" \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nDiscontinue chelation therapy \\n \\n \\n \\n \\n \\nX \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nDiscontinue zinc therapy \\n \\nX \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nAdministration of Study \\n\"}, {\"id\": \"dosing_19\", \"treatmentName\": \"ALXN1840\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 30.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"sourceText\": \" \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nAdministration of Study \\nInterventionm \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nALXN1840 15 mg/day \\n \\n \\n \\n \\n \\n \\nX X \\nX X X \\nX \\nX \\nX X \\nX \\n \\n \\n \\n \\n \\n \\n \\n \\n\"}, {\"id\": \"dosing_20\", \"treatmentName\": \"administered with\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 240.0, \"unit\": \"ml\"}], \"sourceText\": \"’s discretion. \\nl Height at screening only. \\nm While in the CRU, study intervention will be administered after an overnight fast (ie, at least 10 hours) at the same time every morning; drug is to be \\n\"}, {\"id\": \"dosing_21\", \"treatmentName\": \"single\", \"frequency\": \"Q4W\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"ml\"}], \"durationDescription\": \"4 weeks\", \"sourceText\": \"visits in the SoA, females of childbearing \\npotential will be required to perform urine pregnancy tests at least every 4 weeks at their home or the study site throughout their time in the study. \\nt A \"}, {\"id\": \"dosing_22\", \"treatmentName\": \"injected with\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 30.0, \"unit\": \"mg\"}, {\"amount\": 3.0, \"unit\": \"mg\"}, {\"amount\": 7.0, \"unit\": \"mg\"}], \"durationDescription\": \"5 days\", \"sourceText\": \"table tetrathiomolybdate- \\ncopper-albumin TPC (Weiss, 2017).  \\nDepletion of copper by ALXN1840 has been shown to occur primarily through fecal elimination \\nin both healthy and WD animal models. Sheep \"}, {\"id\": \"dosing_23\", \"treatmentName\": \"of approximately\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 3.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}, {\"amount\": 7.0, \"unit\": \"mg\"}], \"durationDescription\": \"5 days\", \"sourceText\": \"h healthy and WD animal models. Sheep injected with 30 mg/day of tetrathiomolybdate for \\n5 days were shown to have an elevation of fecal copper during the treatment period increasing \\nfrom a baseline \"}, {\"id\": \"dosing_24\", \"treatmentName\": \"to approximately\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 7.0, \"unit\": \"mg\"}, {\"amount\": 3.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"durationDescription\": \"5 days\", \"sourceText\": \"s. Sheep injected with 30 mg/day of tetrathiomolybdate for \\n5 days were shown to have an elevation of fecal copper during the treatment period increasing \\nfrom a baseline of approximately 3 mg/day up \"}, {\"id\": \"dosing_25\", \"treatmentName\": \"at\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 5.0, \"unit\": \"mg\"}, {\"amount\": 0.4, \"unit\": \"mg\"}, {\"amount\": 25.0, \"unit\": \"mg\"}, {\"amount\": 4.0, \"unit\": \"mg\"}], \"durationDescription\": \"5 weeks\", \"sourceText\": \"ese studies indicated that only 30% ‑ 40% of \\ncopper remained after 5 weeks of treatment. Similar liver decoppering (approximately \\n40% - 60%) was also reported in toxic milk mice (a WD animal model) \"}, {\"id\": \"dosing_26\", \"treatmentName\": \"initiated at\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 60.0, \"unit\": \"mg\"}], \"sourceText\": \"ified Wilson Disease Rating Scale (UWDRS, Parts II and III) and \\nstabilization of liver function (Weiss, 2017). Treatment with ALXN1840 resulted in an \\nacceptable safety and tolerability profile when \"}, {\"id\": \"dosing_27\", \"treatmentName\": \"administration of\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 60.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"sourceText\": \" safety and tolerability profile when initiated at 15 mg daily with Investigator-driven, \\nindividual participant titration of dose based on safety, NCCcorrected, and symptoms.  \\nFollowing single-dose \"}, {\"id\": \"dosing_28\", \"treatmentName\": \"initiated on\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"durationDescription\": \"28 days\", \"sourceText\": \"ment will be discontinued from their decoppering therapies starting on Day -4 to allow a \\nbaseline assessment of copper/molybdenum balance prior to ALXN1840 treatment. On Day 1, \\nparticipants will be \"}, {\"id\": \"dosing_29\", \"treatmentName\": \"for both\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"durationDescription\": \"15 days\", \"sourceText\": \"elimination and copper balance. \\nCollection periods for feces and urine will vary in duration from 3 to 15 days to support \\nassessment of both copper and molybdenum balance before and at steady state \"}, {\"id\": \"dosing_30\", \"treatmentName\": \"on the\", \"frequency\": \"QOD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"durationDescription\": \"4 weeks\", \"sourceText\": \"rease to 30 mg after \\n4 weeks, unless there are safety concerns that, \\nin the opinion of the Investigator(s) and/or \\nAlexion, may place participants at undue risk, \\nin which case, patients may remain \"}, {\"id\": \"dosing_31\", \"treatmentName\": \"range limit\", \"frequency\": \"QOD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"sourceText\": \" that, \\nin the opinion of the Investigator(s) and/or \\nAlexion, may place participants at undue risk, \\nin which case, patients may remain on the \\n15 mg/day dose for the duration of the study. \\n• \\nDose \"}, {\"id\": \"dosing_32\", \"treatmentName\": \"day \\nto\", \"frequency\": \"QOD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 30.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"sourceText\": \"Investigator(s) and/or \\nAlexion, may place participants at undue risk, \\nin which case, patients may remain on the \\n15 mg/day dose for the duration of the study. \\n• \\nDose range limit 15 mg every other \"}, {\"id\": \"dosing_33\", \"treatmentName\": \"and initial\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}], \"sourceText\": \"et control and sampling, the study is planned to be conducted \\nin a small number of participants with WD who will be admitted to a CRU for 2 inpatient \\nperiods. Inpatient Period 1 includes a baseline \"}, {\"id\": \"dosing_34\", \"treatmentName\": \"balance at\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"sourceText\": \"s a baseline and initial 15 mg/day collection period during the \\naccumulation phase followed by an Outpatient Period; Inpatient Period 2 with a second \\ncollection period to support analysis of copper \"}, {\"id\": \"dosing_35\", \"treatmentName\": \"both the\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"sourceText\": \"s measured closer to 51 hours. With a half-life within this range, the sample collection \\nperiods include assessment of copper and molybdenum balance both during accumulation and at \\nsteady state for \"}, {\"id\": \"dosing_36\", \"treatmentName\": \"or\", \"frequency\": \"Single\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 60.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"sourceText\": \"01-102. In addition, preliminary data from Study WTX101-106 have \\nalso shown ALXN1840 to be well tolerated in healthy Japanese and non-Japanese male and \\nfemale participants at a single dose of 15 mg \"}, {\"id\": \"dosing_37\", \"treatmentName\": \"doses were\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 300.0, \"unit\": \"mg\"}, {\"amount\": 60.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"sourceText\": \" been tested \\nin a range of oncologic indications with a maximum tolerated dose of 300 mg/day (Lowndes, \\n2008). \\nIn the Phase 2 Study WTX101-201 conducted in participants with WD, the daily ALXN1840 \\n\"}, {\"id\": \"dosing_38\", \"treatmentName\": \"to\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 60.0, \"unit\": \"mg\"}], \"sourceText\": \"46%) participants, and 60 mg (32%) \\nfor 9 participants at Week 24 when the primary endpoint assessment was conducted, or at the last \\ndose received for participants with early discontinuation. The 15 \"}, {\"id\": \"dosing_39\", \"treatmentName\": \"range from\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 60.0, \"unit\": \"mg\"}], \"sourceText\": \"1 in participants with WD has been testing the efficacy and safety of ALXN1840 at \\n\\n\\nProtocol Amendment 3.1 (US) \\n \\nALXN1840-WD-204 \\n18 Mar 2022 \\nPage 30 of 74 \\nAlexion Confidential \\na dose titration \"}, {\"id\": \"dosing_40\", \"treatmentName\": \"ranging from\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 60.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"durationDescription\": \"4 weeks\", \"sourceText\": \"tarted at a dose of \\n15 mg/day and, after review of all safety information, participants may be titrated up to \\n30 mg/day after approximately 4 weeks. Based on the results of Study WTX101-201, doses \\n\"}, {\"id\": \"dosing_41\", \"treatmentName\": \"day to\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 60.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"durationDescription\": \"4 weeks\", \"sourceText\": \" \\n15 mg/day and, after review of all safety information, participants may be titrated up to \\n30 mg/day after approximately 4 weeks. Based on the results of Study WTX101-201, doses \\nranging from 15 mg/\"}, {\"id\": \"dosing_42\", \"treatmentName\": \"of the\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg\"}, {\"amount\": 30.0, \"unit\": \"mg\"}], \"sourceText\": \" dosing duration required \\nto result in adequate copper elimination to drive a measurable net negative copper balance. \\nCopper balance will be assessed for the 15 mg/day dose at the beginning and end \"}, {\"id\": \"dosing_43\", \"treatmentName\": \"more than\", \"frequency\": \"QW\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 14.0, \"unit\": \"units\"}], \"durationDescription\": \"1 year\", \"sourceText\": \"ol abuse within 1 year prior to the \\nScreening Visit, or clinical evidence of substance and/or alcohol abuse within the 2 years \\nbefore screening. Alcohol abuse is defined as regular weekly intake of \"}]"
              },
              {
                "id": "35ad0e59-eb9d-4021-9e6a-c728c23a4ebd",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-visitWindows",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"visit_4\", \"visitName\": \"screening\", \"targetDay\": -14, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 1, \"sourceText\": \"treatment-naïve participants are eligible for this study. Following screening and enrollment, \\nparticipants will have a Run-in Period to support diet equilibration (Day -7 through Day -5) and \\nmeasure\"}, {\"id\": \"visit_2\", \"visitName\": \"baseline\", \"targetDay\": 0, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 2, \"sourceText\": \"periods versus the pretreatment baseline in \\nparticipants with WD \\nChange in mean daily copper balance as measured by the \"}, {\"id\": \"visit_1\", \"visitName\": \"Early Termination\", \"targetDay\": 1, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 3, \"sourceText\": \"Assess net copper balance with daily repeat-dose \\nALXN1840 treatment (15 mg and 30 mg) in \\nparticipants with Wilson disease (WD) \"}, {\"id\": \"visit_3\", \"visitName\": \"Day 1\", \"targetDay\": 1, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 4, \"sourceText\": \"Note: The accumulation period refers to time from initiation of ALXN1840 (Day 1) to expected steady state at Day \\n10, based on 5 times the half-life of 2 days.   \\nOverall Design \"}, {\"id\": \"visit_13\", \"visitName\": \"End of Study\", \"targetDay\": 54, \"windowBefore\": 2, \"windowAfter\": 2, \"isRequired\": true, \"visitNumber\": 17, \"sourceText\": \"End of Study Visit Day 54 +/- 2 days  \\nAbbreviations: AP = accumulation period; CRU = clinical research unit; EOS = End of Study; I/O = input/output; \\nPD = pharmacodynamic; PK = pharmacokinetic; SS = \"}, {\"id\": \"visit_18\", \"visitName\": \"Day 7\", \"targetDay\": 7, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 6, \"sourceText\": \"Day 7, indicating the possibility of tissue accumulation, particularly in the setting of high liver \\ncopper concentration (Plitz, 2019).  \\nIf the half-life of ALXN1840 in liver were longer than that o\"}, {\"id\": \"visit_7\", \"visitName\": \"Day 9\", \"targetDay\": 9, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 7, \"sourceText\": \"Participants may be discharged from the clinical research unit (CRU) on Day 9 to return on Day \\n22 or Day 23 (predose); all procedures will start on Day 23. To ensure flexibility, the Outpatient \\nPeri\"}, {\"id\": \"visit_16\", \"visitName\": \"Day 14\", \"targetDay\": 14, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 8, \"sourceText\": \"g A single outpatient visit or phone call and safety laboratory assessment should occur between Day 14 and Day 18. A phone call may take place on a different \\nday than the blood draw within the Day 14\"}, {\"id\": \"visit_9\", \"visitName\": \"Day 22\", \"targetDay\": 22, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 9, \"sourceText\": \"who are discharged will be re-admitted on Day 22 or Day 23 for Treatment Period 2 and will remain in house \\nuntil Day 40. To ensure flexibility, the Outpatient Period may be extended up to an addition\"}, {\"id\": \"visit_6\", \"visitName\": \"Day 23\", \"targetDay\": 23, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 10, \"sourceText\": \"data through Day 23 for each participant. \\nParticipants will have intake and output collection periods from Day -4 through Day -1, from \\nDay 1 through Day 8 (initial 15 mg/day collection period), and \"}, {\"id\": \"visit_11\", \"visitName\": \"Day 25\", \"targetDay\": 25, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 11, \"sourceText\": \"Day 25 through Day 39 (Days 25 through 28, I/O for 15 mg; Days 29 through 39, I/O for 30 mg) \\n5. During these periods all intake (including food and drink) and output (including urine and feces) will \"}, {\"id\": \"visit_5\", \"visitName\": \"Day 29\", \"targetDay\": 29, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 12, \"sourceText\": \"treatment period of approximately 28 days followed by titration up to 30 mg/day on Day 29. \\nBefore titration to 30 mg/day, the Safety Review Committee (SRC) will review available safety \\ndata through \"}, {\"id\": \"visit_17\", \"visitName\": \"Day 36\", \"targetDay\": 36, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 13, \"sourceText\": \"Day 36 through Day 39 for the 30 mg/day dose: if steady state is achieved, molybdenum(out) \\nwill equal molybdenum(in). \\n2.2. \"}, {\"id\": \"visit_8\", \"visitName\": \"Day 39\", \"targetDay\": 39, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 14, \"sourceText\": \"through Day 39. \\n2. Participants will be admitted to the CRU for Treatment Period 1 on Day -8 and may be discharged on Day 9 \\nor remain in the CRU for their own safety or to maintain the integrity of \"}, {\"id\": \"visit_10\", \"visitName\": \"Day 40\", \"targetDay\": 40, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 15, \"sourceText\": \"until Day 40. To ensure flexibility, the Outpatient Period may be extended up to an additional 14 days with \\nInvestigator approval. In this situation, participants will be given additional investigati\"}, {\"id\": \"visit_12\", \"visitName\": \"Day 54\", \"targetDay\": 54, \"windowBefore\": 2, \"windowAfter\": 2, \"isRequired\": true, \"visitNumber\": 16, \"sourceText\": \"End of Study Visit Day 54 +/- 2 days  \\nAbbreviations: AP = accumulation period; CRU = clinical research unit; EOS = End of Study; I/O = input/output; \\nPD = pharmacodynamic; PK = pharmacokinetic; SS = \"}, {\"id\": \"visit_19\", \"visitName\": \"Week 24\", \"targetDay\": 162, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 18, \"targetWeek\": 24, \"sourceText\": \"for 9 participants at Week 24 when the primary endpoint assessment was conducted, or at the last \\ndose received for participants with early discontinuation. The 15 to 60 mg/day dose range has \\nbeen de\"}, {\"id\": \"visit_15\", \"visitName\": \"Follow-up\", \"targetDay\": 365, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 19, \"sourceText\": \"Day 54 follow-up. \\nf Discharge from the unit may occur after completion of all procedures on Day 9 and on Day 40 and after the Investigator has reviewed all safety assessment \\n(including safety labora\"}]"
              },
              {
                "id": "6b334f7a-a339-44bc-9484-c4dfef6a7243",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-activityBindings",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"binding_1\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_1\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day -8 to Day 9\"}, {\"id\": \"binding_2\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_2\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day -8 to Day 9\"}, {\"id\": \"binding_3\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_3\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day 23 to Day 40\"}, {\"id\": \"binding_4\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_4\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day 23 to Day 40\"}, {\"id\": \"binding_5\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_5\", \"expectedOccurrences\": 3, \"sourceText\": \"Daily controlled_meal from Day -7 to Day -5\"}, {\"id\": \"binding_6\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_6\", \"expectedOccurrences\": 4, \"sourceText\": \"Daily controlled_meal from Day -4 to Day -1\"}, {\"id\": \"binding_7\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_7\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day -8 to Day 9\"}, {\"id\": \"binding_8\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_8\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day 23 to Day 40\"}, {\"id\": \"binding_9\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_9\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day -8 to Day 9\"}, {\"id\": \"binding_10\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_10\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily controlled_meal from Day 23 to Day 40\"}, {\"id\": \"binding_11\", \"activityId\": \"controlled_meal\", \"activityName\": \"controlled diet\", \"repetitionId\": \"rep_daily_bound_11\", \"expectedOccurrences\": 13, \"sourceText\": \"Daily controlled_meal from Day 3 to Day 15\"}, {\"id\": \"binding_12\", \"activityId\": \"balance_collection\", \"activityName\": \"copper balance\", \"repetitionId\": \"rep_daily_bound_12\", \"expectedOccurrences\": 101, \"sourceText\": \"Daily balance_collection from Day 101 to Day 201\"}, {\"id\": \"binding_13\", \"activityId\": \"balance_collection\", \"activityName\": \"copper balance\", \"repetitionId\": \"rep_daily_bound_13\", \"expectedOccurrences\": 4, \"sourceText\": \"Daily balance_collection from Day -4 to Day -1\"}, {\"id\": \"binding_14\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_14\", \"expectedOccurrences\": 3, \"sourceText\": \"Daily balance_collection from Day -7 to Day -5\"}, {\"id\": \"binding_15\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_15\", \"expectedOccurrences\": 4, \"sourceText\": \"Daily balance_collection from Day -4 to Day -1\"}, {\"id\": \"binding_16\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_16\", \"expectedOccurrences\": 4, \"sourceText\": \"Daily balance_collection from Day -4 to Day -1\"}, {\"id\": \"binding_17\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_17\", \"expectedOccurrences\": 8, \"sourceText\": \"Daily balance_collection from Day 1 to Day 8\"}, {\"id\": \"binding_18\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_18\", \"expectedOccurrences\": 15, \"sourceText\": \"Daily balance_collection from Day 25 to Day 39\"}, {\"id\": \"binding_19\", \"activityId\": \"balance_collection\", \"activityName\": \"copper balance\", \"repetitionId\": \"rep_daily_bound_19\", \"expectedOccurrences\": 101, \"sourceText\": \"Daily balance_collection from Day 101 to Day 201\"}, {\"id\": \"binding_20\", \"activityId\": \"balance_collection\", \"activityName\": \"copper balance\", \"repetitionId\": \"rep_daily_bound_20\", \"expectedOccurrences\": 101, \"sourceText\": \"Daily balance_collection from Day 101 to Day 201\"}, {\"id\": \"binding_21\", \"activityId\": \"balance_collection\", \"activityName\": \"copper balance\", \"repetitionId\": \"rep_daily_bound_21\", \"expectedOccurrences\": 4, \"sourceText\": \"Daily balance_collection from Day -4 to Day -1\"}, {\"id\": \"binding_22\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_22\", \"expectedOccurrences\": 3, \"sourceText\": \"Daily balance_collection from Day -7 to Day -5\"}, {\"id\": \"binding_23\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_23\", \"expectedOccurrences\": 4, \"sourceText\": \"Daily balance_collection from Day -4 to Day -1\"}, {\"id\": \"binding_24\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_24\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily balance_collection from Day -8 to Day 9\"}, {\"id\": \"binding_25\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_25\", \"expectedOccurrences\": 18, \"sourceText\": \"Daily balance_collection from Day 23 to Day 40\"}, {\"id\": \"binding_26\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_26\", \"expectedOccurrences\": 4, \"sourceText\": \"Daily balance_collection from Day -4 to Day -1\"}, {\"id\": \"binding_27\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_27\", \"expectedOccurrences\": 8, \"sourceText\": \"Daily balance_collection from Day 1 to Day 8\"}, {\"id\": \"binding_28\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_28\", \"expectedOccurrences\": 15, \"sourceText\": \"Daily balance_collection from Day 25 to Day 39\"}, {\"id\": \"binding_29\", \"activityId\": \"balance_collection\", \"activityName\": \"copper balance\", \"repetitionId\": \"rep_daily_bound_29\", \"expectedOccurrences\": 13, \"sourceText\": \"Daily balance_collection from Day 3 to Day 15\"}, {\"id\": \"binding_30\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_30\", \"expectedOccurrences\": 13, \"sourceText\": \"Daily balance_collection from Day 3 to Day 15\"}, {\"id\": \"binding_31\", \"activityId\": \"balance_collection\", \"activityName\": \"molybdenum balance\", \"repetitionId\": \"rep_daily_bound_31\", \"expectedOccurrences\": 201, \"sourceText\": \"Daily balance_collection from Day 101 to Day 301\"}, {\"id\": \"binding_32\", \"activityId\": \"balance_collection\", \"activityName\": \"copper \\nbalance\", \"repetitionId\": \"rep_daily_bound_32\", \"expectedOccurrences\": 3, \"sourceText\": \"Daily balance_collection from Day 3 to Day 5\"}, {\"id\": \"binding_33\", \"activityId\": \"balance_collection\", \"activityName\": \"copper balance\", \"repetitionId\": \"rep_daily_bound_33\", \"expectedOccurrences\": 101, \"sourceText\": \"Daily balance_collection from Day 101 to Day 201\"}]"
              },
              {
                "id": "b3cd03e8-5bc9-44a7-b97f-08ff8977d9e7",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-titrationSchedules",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"titration_1\", \"titrationType\": \"escalation\", \"doseLevels\": [{\"doseValue\": \"15 mg\", \"startDay\": 1, \"endDay\": 28, \"sourceText\": \"15 mg/day for approximately 28 days, then titrating up to 30 mg\"}, {\"doseValue\": \"30 mg\", \"startDay\": 29, \"requiresPriorDose\": \"15 mg\", \"transitionRule\": \"After 28 days on 15 mg\", \"sourceText\": \"15 mg/day for approximately 28 days, then titrating up to 30 mg\"}], \"interventionName\": \"ALXN1840 Treatment\", \"sourceText\": \"15 mg/day for approximately 28 days, then titrating up to 30 mg\"}]"
              },
              {
                "id": "452c77b7-a00b-44fb-be1e-de71b5865752",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-analysisWindows",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"window_baseline_1\", \"windowType\": \"baseline\", \"name\": \"Baseline Period\", \"startDay\": 4, \"endDay\": -1, \"description\": \"Pre-treatment baseline from Day 4 to Day -1\", \"sourceText\": \"Baseline Day -4 through Day -1\"}]"
              },
              {
                "id": "e2004311-8cbe-42d0-8a33-6d0ebbf22ad8",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-integrityIssues",
                "instanceType": "ExtensionAttribute",
                "valueString": "[\"INTEGRITY: Repetition 'rep_window_2' has positive offset but source mentions negative day\", \"INTEGRITY: Repetition 'rep_window_3' has positive offset but source mentions negative day\", \"INTEGRITY: Repetition 'rep_window_17' has positive offset but source mentions negative day\", \"INTEGRITY: Repetition 'rep_window_22' has positive offset but source mentions negative day\"]"
              }
            ],
            "epochs": [
              {
                "id": "98bcd3bc-a36a-4e7d-a299-416af69de801",
                "name": "Early Termination",
                "instanceType": "StudyEpoch",
                "description": "Early Termination - terminal epoch for subject path completion",
                "type": {
                  "id": "c91e2fcb-f083-4b84-b096-ef6b4a7bc108",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              }
            ]
          }
        ],
        "titles": [
          {
            "id": "3abc571b-8838-4ddd-b99f-a8fbdbcec5e1",
            "text": "A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants with Wilson Disease Treated with ALXN1840",
            "type": {
              "id": "0becc241-df87-47a4-ad97-b1753ff1291a",
              "code": "Official Study Title",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Official Study Title",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          },
          {
            "id": "cbd6089c-08b7-43cd-b6c3-a761ec9d9425",
            "text": "Copper and Molybdenum Balance in Participants with Wilson Disease Treated with ALXN1840",
            "type": {
              "id": "2b30db4a-a5cc-49df-91aa-309d0764e146",
              "code": "Brief Study Title",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Brief Study Title",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          }
        ],
        "studyIdentifiers": [
          {
            "id": "82948af3-dd9c-4a30-966f-926aee974c28",
            "text": "ALXN1840-WD-204",
            "instanceType": "StudyIdentifier",
            "scopeId": "cac07fb3-7954-4d19-9307-969521695ccd",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "6ec18f5e-146e-4954-8202-cf075681af6b",
            "text": "2020-001104-41",
            "instanceType": "StudyIdentifier",
            "scopeId": "cac07fb3-7954-4d19-9307-969521695ccd",
            "type": {
              "code": "C98714",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinical Trial Registry Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "d0df534e-ef47-4c40-bb25-a31e037299b9",
            "text": "119006",
            "instanceType": "StudyIdentifier",
            "scopeId": "cac07fb3-7954-4d19-9307-969521695ccd",
            "type": {
              "code": "C218685",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "US FDA Investigational New Drug Application Number",
              "instanceType": "Code"
            }
          },
          {
            "id": "12f5ef45-61b9-4d37-b290-105fd89ef161",
            "text": "NCT04573309",
            "instanceType": "StudyIdentifier",
            "scopeId": "cac07fb3-7954-4d19-9307-969521695ccd",
            "type": {
              "code": "C172240",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinicaltrials.gov Identifier",
              "instanceType": "Code"
            }
          }
        ],
        "studyPhase": {
          "id": "827e7eb5-6b86-465e-b049-040f30c57f46",
          "code": "Phase2",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Phase2",
          "instanceType": "Code"
        },
        "rationale": "Protocol version"
      }
    ],
    "organizations": [
      {
        "id": "31d64c3e-abd7-472d-80c5-d1d5feadb4ef",
        "name": "Alexion Pharmaceuticals, Inc.",
        "type": {
          "id": "b514bf12-c0a0-4ff3-a46f-aa92beb321ec",
          "code": "Pharmaceutical Company",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Pharmaceutical Company",
          "instanceType": "Code"
        },
        "instanceType": "Organization"
      }
    ],
    "indications": [
      {
        "id": "b122586e-7b30-46d1-9eba-4d366e1a2444",
        "name": "Wilson Disease",
        "isRareDisease": false,
        "instanceType": "Indication",
        "description": "Participants with Wilson Disease"
      }
    ],
    "name": "A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants with Wilson Disease Treated with ALXN1840"
  },
  "administrableProducts": [
    {
      "id": "71a31d51-a18c-4b74-acf4-7b92694b094d",
      "name": "ALXN1840",
      "instanceType": "AdministrableProduct",
      "doseForm": {
        "id": "8bfc6a09-27d6-4302-96ce-0be52549ca48",
        "code": "Tablet",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Tablet",
        "instanceType": "Code"
      },
      "strength": "15 mg",
      "substanceIds": [
        "d1e93da0-7a11-4fb5-ab6b-4809cf8b9a40"
      ],
      "manufacturer": "Alexion"
    }
  ],
  "administrations": [
    {
      "id": "6860472d-3745-4d9d-82e4-0291222b89e8",
      "name": "ALXN1840 initial dose",
      "instanceType": "Administration",
      "dose": "15 mg",
      "doseFrequency": "once daily",
      "route": {
        "id": "358cf79f-fe82-4d67-8c66-d35116ba9f87",
        "code": "Oral",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Oral",
        "instanceType": "Code"
      },
      "duration": "Approximately 28 days (Day 1 through Day 28)"
    },
    {
      "id": "573be4aa-1fb3-45c5-bdeb-e99033ba9527",
      "name": "ALXN1840 titrated dose",
      "instanceType": "Administration",
      "dose": "30 mg",
      "doseFrequency": "once daily",
      "route": {
        "id": "935fcbc2-90b6-41ea-8357-867f31fb3d0b",
        "code": "Oral",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Oral",
        "instanceType": "Code"
      },
      "duration": "From Day 29 through Day 39"
    },
    {
      "id": "00347f77-77d0-407d-98d8-e66b342d7305",
      "name": "ALXN1840 dose reduction",
      "instanceType": "Administration",
      "dose": "15 mg",
      "doseFrequency": "every other day",
      "route": {
        "id": "96c5ad52-892f-4294-ad89-57f88c96c825",
        "code": "Oral",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Oral",
        "instanceType": "Code"
      },
      "duration": "Dose modification for specific adverse events until resolution of abnormality."
    }
  ],
  "substances": [
    {
      "id": "d1e93da0-7a11-4fb5-ab6b-4809cf8b9a40",
      "name": "bis-choline tetrathiomolybdate",
      "instanceType": "Substance",
      "description": "Active ingredient of ALXN1840. Also referred to as WTX101."
    },
    {
      "id": "c34a646b-1f72-42ea-a07d-bf75eee3ad16",
      "name": "tetrathiomolybdic acid",
      "instanceType": "Substance",
      "description": "Each 15 mg ALXN1840 tablet contains 7.8 mg of tetrathiomolybdic acid."
    }
  ],
  "narrativeContents": [
    {
      "id": "ed3434ba-33e3-4968-b3b9-6c4a5eafe3f7",
      "name": "PROTOCOL SUMMARY",
      "order": 0,
      "instanceType": "NarrativeContent",
      "sectionNumber": "1",
      "sectionTitle": "PROTOCOL SUMMARY",
      "sectionType": {
        "id": "8a73e26b-e8c9-457f-886d-eba82627a14e",
        "code": "Synopsis",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Synopsis",
        "instanceType": "Code"
      },
      "childIds": [
        "89130a1f-de9d-4340-b55c-dd78a2170d53",
        "5ca04424-9f6b-4e59-bc38-fbc15402f258",
        "8d9948a0-cd17-42bd-9115-e812b421c95b"
      ]
    },
    {
      "id": "76e07dc1-54a9-4c9a-a8b4-dd50526f471c",
      "name": "INTRODUCTION",
      "order": 1,
      "instanceType": "NarrativeContent",
      "sectionNumber": "2",
      "sectionTitle": "INTRODUCTION",
      "sectionType": {
        "id": "44fe88c8-11ee-4d48-bb2c-39f2934885a6",
        "code": "Introduction",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Introduction",
        "instanceType": "Code"
      },
      "childIds": [
        "7af1d073-8190-45b0-b8c0-68c4aae66d91",
        "dcbdff44-4b59-4cda-b0da-0c9855db129c",
        "224f77c9-7558-462d-881d-677a2a66c73b"
      ]
    },
    {
      "id": "20a5aa51-c23a-4fa5-838f-9de2188acd26",
      "name": "OBJECTIVES AND ENDPOINTS",
      "order": 2,
      "instanceType": "NarrativeContent",
      "sectionNumber": "3",
      "sectionTitle": "OBJECTIVES AND ENDPOINTS",
      "sectionType": {
        "id": "5f6d5476-7557-4e92-9952-6938976a97df",
        "code": "Objectives",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Objectives",
        "instanceType": "Code"
      }
    },
    {
      "id": "14be10b4-b74f-4b64-b3a3-775eb2e36d96",
      "name": "STUDY DESIGN",
      "order": 3,
      "instanceType": "NarrativeContent",
      "sectionNumber": "4",
      "sectionTitle": "STUDY DESIGN",
      "sectionType": {
        "id": "7c603265-a15c-4c2f-9868-069c28ed140a",
        "code": "Study Design",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Study Design",
        "instanceType": "Code"
      },
      "childIds": [
        "d94fba69-3c1f-45cf-96bf-1e44cc3090ed",
        "1494e8a1-b2c7-4a37-b75a-18d96f9822ac",
        "fdef69b2-a88b-4b81-9c76-505c9540c87f",
        "5c8b3b87-011f-496c-af7b-a59e0d57b7d5"
      ]
    },
    {
      "id": "1b3e6f7b-76f2-460c-8c25-917b7cdca11d",
      "name": "STUDY POPULATION",
      "order": 4,
      "instanceType": "NarrativeContent",
      "sectionNumber": "5",
      "sectionTitle": "STUDY POPULATION",
      "sectionType": {
        "id": "57566a6d-bbe7-48cd-a733-ea50a5d7cbb4",
        "code": "Study Population",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Study Population",
        "instanceType": "Code"
      },
      "childIds": [
        "7829d705-9713-45a7-bfd1-92259581678d",
        "c56472b1-cf24-4f0a-98a5-bd6bd20c4a5f",
        "3aef0410-c4fa-4593-a304-333e147d0295",
        "37b734e9-709f-44ba-8563-17654ab1479c"
      ]
    },
    {
      "id": "27088eee-0445-42cb-ac37-dfb42220c7fd",
      "name": "STUDY INTERVENTION",
      "order": 5,
      "instanceType": "NarrativeContent",
      "sectionNumber": "6",
      "sectionTitle": "STUDY INTERVENTION",
      "sectionType": {
        "id": "2076c90f-75d1-413d-a714-841590e96bea",
        "code": "Treatment",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Treatment",
        "instanceType": "Code"
      }
    },
    {
      "id": "aff7776e-b653-47e8-a409-12eb83513c1b",
      "name": "Study and Site Start and Closure",
      "order": 6,
      "instanceType": "NarrativeContent",
      "sectionNumber": "10.1.8",
      "sectionTitle": "Study and Site Start and Closure",
      "sectionType": {
        "id": "47265523-2f0c-4f7a-8e18-ec56f065312d",
        "code": "Other",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Other",
        "instanceType": "Code"
      }
    },
    {
      "id": "30096ac8-6a6d-4e8c-98e0-c438b3465ee5",
      "name": "Publication Policy",
      "order": 7,
      "instanceType": "NarrativeContent",
      "sectionNumber": "10.1.9",
      "sectionTitle": "Publication Policy",
      "sectionType": {
        "id": "a20c5056-3f29-40c2-b010-e97620ac9102",
        "code": "Ethics",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Ethics",
        "instanceType": "Code"
      }
    },
    {
      "id": "0125e40a-45b7-436e-8c2a-05a1c67f269f",
      "name": "Clinical Laboratory Tests",
      "order": 8,
      "instanceType": "NarrativeContent",
      "sectionNumber": "10.2",
      "sectionTitle": "Clinical Laboratory Tests",
      "sectionType": {
        "id": "b51a51bc-6184-48e0-867a-79b8452672cc",
        "code": "Assessments",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Assessments",
        "instanceType": "Code"
      }
    },
    {
      "id": "441519c1-5469-4806-a0f4-caa30d03ecc0",
      "name": "Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
      "order": 9,
      "instanceType": "NarrativeContent",
      "sectionNumber": "10.3",
      "sectionTitle": "Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
      "sectionType": {
        "id": "3a55915e-3f7a-48ba-8b3e-50aef8623260",
        "code": "Safety",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Safety",
        "instanceType": "Code"
      },
      "childIds": [
        "c19268a8-84f2-45d6-bbed-ce291dda599a",
        "d5bfd838-104f-49af-bb25-8eb0bfb0014f",
        "e523a7cc-6aeb-4f6e-a090-f35ae5a12f22",
        "16df8071-8193-4205-84ca-efd41e60ccce"
      ]
    },
    {
      "id": "6b5d6a33-f2a0-423a-a236-7d745dede953",
      "name": "Contraceptive Guidance and Collection of Pregnancy Information",
      "order": 10,
      "instanceType": "NarrativeContent",
      "sectionNumber": "10.4",
      "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
      "sectionType": {
        "id": "a7b5583f-990f-46b9-b2bb-a5a76bc53b16",
        "code": "Safety",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Safety",
        "instanceType": "Code"
      },
      "childIds": [
        "27eb51af-99ee-4e44-b580-ff8530dff20c",
        "d1492e2b-7917-4af5-a43c-a2facde388e6"
      ]
    },
    {
      "id": "fa43b8ba-1fb3-49ec-bbc7-b8fd950abe46",
      "name": "COVID-19 Vaccine Risk Assessment",
      "order": 11,
      "instanceType": "NarrativeContent",
      "sectionNumber": "10.5",
      "sectionTitle": "COVID-19 Vaccine Risk Assessment",
      "sectionType": {
        "id": "3ee38897-d765-432d-ac2f-aafd1455eb72",
        "code": "Safety",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Safety",
        "instanceType": "Code"
      }
    },
    {
      "id": "08d90133-b7f4-419b-bf82-d345b36ec585",
      "name": "Abbreviations",
      "order": 12,
      "instanceType": "NarrativeContent",
      "sectionNumber": "10.6",
      "sectionTitle": "Abbreviations",
      "sectionType": {
        "id": "8233b3ee-38a4-4dc5-86b2-ca2a275b571a",
        "code": "Other",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Other",
        "instanceType": "Code"
      }
    },
    {
      "id": "acbc2ed8-020c-4c41-971d-d295984e8546",
      "name": "Protocol Amendment History",
      "order": 13,
      "instanceType": "NarrativeContent",
      "sectionNumber": "10.7",
      "sectionTitle": "Protocol Amendment History",
      "sectionType": {
        "id": "fb207655-60f2-48ed-b6ce-1b3bccb56a84",
        "code": "Other",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Other",
        "instanceType": "Code"
      }
    },
    {
      "id": "0a5982b8-b1ca-494a-ab05-03457a2cb43b",
      "name": "REFERENCES",
      "order": 14,
      "instanceType": "NarrativeContent",
      "sectionNumber": "11",
      "sectionTitle": "REFERENCES",
      "sectionType": {
        "id": "60b21f12-9026-45be-a05a-8acf158f4cd0",
        "code": "References",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "References",
        "instanceType": "Code"
      }
    }
  ],
  "abbreviations": [
    {
      "id": "6db11818-0ba1-4f85-9be3-6342d87e9e21",
      "abbreviatedText": "SoA",
      "expandedText": "Schedule of Activities",
      "instanceType": "Abbreviation"
    },
    {
      "id": "9c23e79b-b608-407f-95c3-0af180b07f45",
      "abbreviatedText": "SARS-CoV-2",
      "expandedText": "Coronavirus",
      "instanceType": "Abbreviation"
    },
    {
      "id": "e541ba92-06ce-45df-853b-0914adf6aa9f",
      "abbreviatedText": "AE",
      "expandedText": "Adverse Event",
      "instanceType": "Abbreviation"
    },
    {
      "id": "3800e984-b2a2-4ddc-9bbc-5f2c1f7960b1",
      "abbreviatedText": "SAE",
      "expandedText": "Serious Adverse Event",
      "instanceType": "Abbreviation"
    },
    {
      "id": "d098b480-63a4-4f99-abf5-46ca5bf126c0",
      "abbreviatedText": "COVID-19",
      "expandedText": "Coronavirus (SARS-CoV-2) Disease 2019",
      "instanceType": "Abbreviation"
    },
    {
      "id": "3c8ac7df-257b-484f-8f7d-b5d10b4a549d",
      "abbreviatedText": "WD",
      "expandedText": "Wilson disease",
      "instanceType": "Abbreviation"
    },
    {
      "id": "a0602f16-ce70-431f-af46-c4e56223dbc6",
      "abbreviatedText": "ADME",
      "expandedText": "absorption, distribution, metabolism, and excretion",
      "instanceType": "Abbreviation"
    },
    {
      "id": "e3933de4-0c6d-467b-9162-15bbb927c1b7",
      "abbreviatedText": "PK",
      "expandedText": "plasma pharmacokinetics",
      "instanceType": "Abbreviation"
    },
    {
      "id": "c726a1e2-f2e2-4532-beec-88ad9b85a0d5",
      "abbreviatedText": "NCC",
      "expandedText": "non-ceruloplasmin-bound copper",
      "instanceType": "Abbreviation"
    },
    {
      "id": "cc690e2f-630b-4bbd-ab0e-0449f85f7d27",
      "abbreviatedText": "NCCcorrected",
      "expandedText": "non-ceruloplasmin-bound copper corrected",
      "instanceType": "Abbreviation"
    },
    {
      "id": "76d0ca6c-7650-4a4d-be5a-f5733e61a518",
      "abbreviatedText": "TPC",
      "expandedText": "tetrathiomolybdate- copper -albumin tripartite complex",
      "instanceType": "Abbreviation"
    }
  ],
  "studyDefinitionDocument": {
    "id": "74ba1e21-9cc6-4632-bfa8-05e56d8a04f9",
    "name": "A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants with Wilson Disease Treated with ALXN1840",
    "documentType": "Protocol",
    "language": "en",
    "instanceType": "StudyDefinitionDocument",
    "version": "3.1",
    "versionDate": "2022-03-18",
    "contentIds": [
      "ed3434ba-33e3-4968-b3b9-6c4a5eafe3f7",
      "76e07dc1-54a9-4c9a-a8b4-dd50526f471c",
      "20a5aa51-c23a-4fa5-838f-9de2188acd26",
      "14be10b4-b74f-4b64-b3a3-775eb2e36d96",
      "1b3e6f7b-76f2-460c-8c25-917b7cdca11d",
      "27088eee-0445-42cb-ac37-dfb42220c7fd",
      "aff7776e-b653-47e8-a409-12eb83513c1b",
      "30096ac8-6a6d-4e8c-98e0-c438b3465ee5",
      "0125e40a-45b7-436e-8c2a-05a1c67f269f",
      "441519c1-5469-4806-a0f4-caa30d03ecc0",
      "6b5d6a33-f2a0-423a-a236-7d745dede953",
      "fa43b8ba-1fb3-49ec-bbc7-b8fd950abe46",
      "08d90133-b7f4-419b-bf82-d345b36ec585",
      "acbc2ed8-020c-4c41-971d-d295984e8546",
      "0a5982b8-b1ca-494a-ab05-03457a2cb43b"
    ]
  },
  "studyAmendments": [
    {
      "id": "f4c702fe-ccf9-42a0-b97b-99fa78153669",
      "number": "3.1 (US)",
      "scope": {
        "id": "6d6e17bf-d8c6-45b8-a2d4-2ce4e394db97",
        "code": "Global",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Global",
        "instanceType": "Code"
      },
      "instanceType": "StudyAmendment",
      "summary": "The main reason for preparation of this amendment was to clarify study procedures occurring across different sites in the US, so as to facilitate participant recruitment across different regions of the US, and to lessen inconvenience for participants without compromising the quality of the study.",
      "effectiveDate": "2022-03-18",
      "reasonIds": [
        "6c1ad738-aae9-465d-8fea-06d5f1602116",
        "28ab59c1-e37a-4d9b-b938-c67a832014b8"
      ],
      "previousVersion": "3",
      "newVersion": "3.1 (US)"
    },
    {
      "id": "5c7564e6-ff7b-4e14-8592-87f6ff133a19",
      "number": "3",
      "scope": {
        "id": "52585143-f37f-4802-933a-53e66c67772e",
        "code": "Global",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Global",
        "instanceType": "Code"
      },
      "instanceType": "StudyAmendment",
      "summary": "The main reason for preparation of this amendment was to update the washout period for zinc.",
      "effectiveDate": "2021-08-31",
      "reasonIds": [
        "7cc5c858-c033-4957-88f7-ce2cf675fabb",
        "dd6594a9-7c12-4cf7-b8d7-725b9b2459d9"
      ],
      "previousVersion": "2",
      "newVersion": "3"
    },
    {
      "id": "1ca2e0c9-bc7e-45e5-96da-ec254a001ad1",
      "number": "2",
      "scope": {
        "id": "1c566013-f68e-4797-83fd-0717651ec8c2",
        "code": "Global",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Global",
        "instanceType": "Code"
      },
      "instanceType": "StudyAmendment",
      "summary": "The main reason for preparation of this amendment was to revise the exclusion criterion for a urine drug screen. Changes implemented via Administrative Letter 1 and Administrative Letter 2, as well as COVID vaccination guidance, have also been incorporated.",
      "effectiveDate": "2021-03-19",
      "reasonIds": [
        "1ef59e3c-359f-46f4-a259-c8eb9df07b3c",
        "4f91db1f-16ef-4702-bc8d-eb7af6a8d888",
        "75169a76-dfdc-4252-a47a-4e206118a9d8",
        "d0869f31-f589-4317-8a8b-332e61d093b7"
      ],
      "previousVersion": "1",
      "newVersion": "2"
    },
    {
      "id": "22e36956-67ff-430d-bc52-54a75ea07a91",
      "number": "1",
      "scope": {
        "id": "7a5bcaae-4897-4a4e-befa-1cb99d1fc53f",
        "code": "Global",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Global",
        "instanceType": "Code"
      },
      "instanceType": "StudyAmendment",
      "summary": "The main reason for preparation of this amendment was to update procedures outlined in the Schedule of Activities, remove contradictory text on the reporting of serious adverse events, and add details of an interim analysis.",
      "effectiveDate": "2020-08-18",
      "reasonIds": [
        "3ae0157c-a979-4c93-9264-d1bf3a100da1",
        "d357c1ed-a32c-4d23-a2e7-7c52a2c1bb0e",
        "fd074e5f-1ef4-4978-b071-594e89d3a0b1",
        "d4877b88-5ae6-47a5-9e80-22f9b0168e8a"
      ],
      "previousVersion": "Original Protocol",
      "newVersion": "1"
    }
  ],
  "geographicScope": {
    "id": "2db895fc-4422-47d5-989a-953061e44f04",
    "name": "Study Geographic Scope",
    "scopeType": "Multinational",
    "instanceType": "GeographicScope",
    "countryIds": [
      "a3c6f4c0-76d3-478e-af80-d29020e2754c"
    ],
    "regions": [
      "North America",
      "Europe"
    ]
  },
  "countries": [
    {
      "id": "a3c6f4c0-76d3-478e-af80-d29020e2754c",
      "name": "United States",
      "instanceType": "Country",
      "code": "US"
    }
  ],
  "procedures": [
    {
      "id": "4afdbcfd-cc19-4748-b2ec-72a022979403",
      "name": "Blood Sampling",
      "instanceType": "Procedure",
      "label": "Blood Draw",
      "description": "Collection of blood samples for pharmacokinetic (PK), pharmacodynamic (PD), serum chemistry, hematology, coagulation, pregnancy tests, and viral screening (HIV, Hepatitis B and C).",
      "procedureType": {
        "id": "655a8798-8ea0-41ef-989d-391325bce61c",
        "code": "Sample Collection",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Sample Collection",
        "instanceType": "Code"
      },
      "code": {
        "id": "d7750a80-db31-4955-b4fa-c749f1fab57b",
        "code": "36415",
        "codeSystem": "CPT",
        "codeSystemVersion": "2024-09-27",
        "decode": "Collection of venous blood by venipuncture",
        "instanceType": "Code"
      }
    },
    {
      "id": "acd48d49-a3a1-4dd6-9b9e-35de12200e19",
      "name": "Urine Collection",
      "instanceType": "Procedure",
      "label": "Urine Sample Collection",
      "description": "Collection of urine for urinalysis, drug screening, pregnancy testing, and 24-hour collection for copper and molybdenum measurement.",
      "procedureType": {
        "id": "e6d48559-3242-4a34-8238-8262d6e395f0",
        "code": "Sample Collection",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Sample Collection",
        "instanceType": "Code"
      }
    },
    {
      "id": "32f5383f-7b0d-47f4-bf7e-bbc0e484330b",
      "name": "Fecal Collection",
      "instanceType": "Procedure",
      "label": "Stool Sample Collection",
      "description": "Collection of fecal samples for measurement of copper and molybdenum content.",
      "procedureType": {
        "id": "991f2fe0-31f1-45f5-b8a6-4f1737801cb9",
        "code": "Sample Collection",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Sample Collection",
        "instanceType": "Code"
      }
    },
    {
      "id": "fc5a845f-1303-465f-9774-a6d1ba491689",
      "name": "Electrocardiogram",
      "instanceType": "Procedure",
      "label": "ECG",
      "description": "Triplicate 12-lead ECG to assess heart rate and intervals (PR, QRS, QT and QTc).",
      "procedureType": {
        "id": "cae7b3df-b35b-49c2-a885-29fc23f12cdb",
        "code": "Diagnostic",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Diagnostic",
        "instanceType": "Code"
      },
      "code": {
        "id": "37feffb2-d3b7-43bf-b304-8445310fa572",
        "code": "93000",
        "codeSystem": "CPT",
        "codeSystemVersion": "2024-09-27",
        "decode": "Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report",
        "instanceType": "Code"
      }
    },
    {
      "id": "9bc8b79b-b3c1-43a1-b6da-db958773b751",
      "name": "Vital Signs Measurement",
      "instanceType": "Procedure",
      "label": "Vital Signs",
      "description": "Assessment of body temperature, heart rate, respiratory rate, and systolic and diastolic blood pressure.",
      "procedureType": {
        "id": "dbab84ac-5c20-4f9c-9587-dfe3539ec965",
        "code": "Monitoring",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Monitoring",
        "instanceType": "Code"
      }
    },
    {
      "id": "756cce20-a68f-41ae-ae2b-e9337a0cb599",
      "name": "Physical Examination",
      "instanceType": "Procedure",
      "label": "Physical Exam",
      "description": "A full physical examination including assessments of the cardiovascular, respiratory, gastrointestinal, and neurological systems. Symptom-driven physical examinations may also be performed.",
      "procedureType": {
        "id": "fcec347f-f79e-49bd-8abd-3aeaf4e59ebb",
        "code": "Assessment",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Assessment",
        "instanceType": "Code"
      }
    },
    {
      "id": "548cc141-983e-469e-9ef1-bd711a62efdf",
      "name": "Oral Drug Administration",
      "instanceType": "Procedure",
      "label": "ALXN1840 Administration",
      "description": "Administration of ALXN1840 tablets, to be swallowed intact with 240 mL of water after an overnight fast.",
      "procedureType": {
        "id": "db9ef5ca-a759-42ea-a451-7e29f6141474",
        "code": "Therapeutic",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Therapeutic",
        "instanceType": "Code"
      }
    },
    {
      "id": "094b0a37-a3fe-417e-8aa6-ff54f89156a6",
      "name": "Clinical Safety Laboratory Assessments",
      "instanceType": "Procedure",
      "label": "Safety Labs",
      "description": "Laboratory assessments including serum chemistry, hematology, coagulation, and urinalysis.",
      "procedureType": {
        "id": "1f1791d8-8e33-4835-aefb-7dbbc38c6cef",
        "code": "Diagnostic",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Diagnostic",
        "instanceType": "Code"
      }
    },
    {
      "id": "597ed3bf-9a58-457f-8813-115c74bdecec",
      "name": "Adverse Event Monitoring",
      "instanceType": "Procedure",
      "label": "AE Monitoring",
      "description": "Collection and follow-up of adverse events (AEs) and serious adverse events (SAEs).",
      "procedureType": {
        "id": "1a838376-3825-492b-9dba-fbcc34b37fc2",
        "code": "Monitoring",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Monitoring",
        "instanceType": "Code"
      }
    },
    {
      "id": "3b989866-7eaa-4d9c-a23e-9b5411efa47d",
      "name": "Alcohol Test",
      "instanceType": "Procedure",
      "label": "Alcohol Test",
      "description": "Screening for alcohol use.",
      "procedureType": {
        "id": "dce1d9fa-e581-49c3-9208-60b477b04446",
        "code": "Diagnostic",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Diagnostic",
        "instanceType": "Code"
      }
    },
    {
      "id": "eadd7c1d-823c-4827-93c3-6a35f55c2f64",
      "name": "Urine Drug Screen",
      "instanceType": "Procedure",
      "label": "Urine Drug Screen",
      "description": "Screening for drug use via urine sample.",
      "procedureType": {
        "id": "5cca5a3a-44a7-40c4-ac52-e81d78606793",
        "code": "Diagnostic",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Diagnostic",
        "instanceType": "Code"
      }
    },
    {
      "id": "2700f20c-ee06-46b5-b954-9958e75a13bf",
      "name": "Food and Fluid Sample Collection",
      "instanceType": "Procedure",
      "label": "Dietary Sample Collection",
      "description": "Collection of samples from all meal and fluid batches for measurement of copper and molybdenum content.",
      "procedureType": {
        "id": "3be6d029-41d5-4c38-bb6a-a1ec8133c280",
        "code": "Sample Collection",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Sample Collection",
        "instanceType": "Code"
      }
    },
    {
      "id": "f181115c-f064-4f55-947d-a0a289bba3dd",
      "name": "Height, Weight, and BMI Measurement",
      "instanceType": "Procedure",
      "label": "Anthropometric Measurements",
      "description": "Measurement of participant's height, weight, and calculation of Body Mass Index (BMI).",
      "procedureType": {
        "id": "cf8a1ca8-3b00-4649-aaa0-180e51be71a8",
        "code": "Assessment",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Assessment",
        "instanceType": "Code"
      }
    },
    {
      "id": "5449871a-9cb0-40d2-a926-8c86cd9fc024",
      "name": "Neurological Monitoring",
      "instanceType": "Procedure",
      "label": "Neurological Monitoring",
      "description": "Regular monitoring for neurologic adverse events and neurological dysfunction.",
      "procedureType": {
        "id": "b05ad24e-056c-4203-ab44-aae1e344359f",
        "code": "Monitoring",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Monitoring",
        "instanceType": "Code"
      }
    },
    {
      "id": "55034bac-283f-4b75-8209-b1fed757e5b0",
      "name": "Informed Consent",
      "instanceType": "Procedure",
      "label": "Informed Consent",
      "description": "Process of obtaining informed consent from the participant before any study-related procedures.",
      "procedureType": {
        "id": "6d302c22-282e-4f62-90da-da582f878dde",
        "code": "Assessment",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Assessment",
        "instanceType": "Code"
      }
    }
  ],
  "medicalDevices": [
    {
      "id": "3b03fe2f-bc7a-4328-8b39-15f2d72d6e58",
      "name": "Cannula",
      "instanceType": "MedicalDevice",
      "label": "Venous Cannula",
      "description": "A cannula may be placed to minimize needle sticks for repeated blood draws.",
      "deviceType": {
        "id": "75f9fd61-f9f4-4fd9-ac0b-a4c35938fd0b",
        "code": "Drug Delivery Device",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Drug Delivery Device",
        "instanceType": "Code"
      }
    },
    {
      "id": "3ad37a0d-10d3-4115-8bfe-98a47ee77e73",
      "name": "Catheter",
      "instanceType": "MedicalDevice",
      "label": "Venous Catheter",
      "description": "A catheter for venous access, not to be left in place for longer than 72 hours.",
      "deviceType": {
        "id": "b3b09e86-a6a7-4635-ae87-2105dbeabf57",
        "code": "Drug Delivery Device",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Drug Delivery Device",
        "instanceType": "Code"
      }
    },
    {
      "id": "3532119e-b71a-4582-bab3-f940cc0958f7",
      "name": "12-lead ECG Machine",
      "instanceType": "MedicalDevice",
      "label": "ECG Machine",
      "description": "Device used to perform triplicate 12-lead electrocardiograms.",
      "deviceType": {
        "id": "774100eb-4ad8-44f7-a773-c9a354fb22d9",
        "code": "Diagnostic Device",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Diagnostic Device",
        "instanceType": "Code"
      }
    },
    {
      "id": "e04ca15f-7f41-4428-9525-51491894ee17",
      "name": "Automated Blood Pressure Device",
      "instanceType": "MedicalDevice",
      "label": "Automated BP Monitor",
      "description": "A completely automated device for assessing blood pressure and heart rate measurements.",
      "deviceType": {
        "id": "91e47d90-b95e-4d03-8d02-9245a27a60d0",
        "code": "Monitoring Device",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Monitoring Device",
        "instanceType": "Code"
      }
    },
    {
      "id": "7c72e134-9341-4c93-9ca4-3d113801a902",
      "name": "Inductively Coupled Plasma Mass Spectrometer",
      "instanceType": "MedicalDevice",
      "label": "ICP-MS",
      "description": "Used to determine the copper and molybdenum concentration of intake (food, fluids) and output (urine, feces) samples.",
      "deviceType": {
        "id": "cd5210d2-1179-496e-ae71-303be5aa38a4",
        "code": "Diagnostic Device",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Diagnostic Device",
        "instanceType": "Code"
      }
    }
  ],
  "ingredients": [
    {
      "id": "d1e86dfa-618d-427f-a8f8-0d44c3eab5cc",
      "name": "ALXN1840",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "06f944ce-0d9e-48bd-8ab3-56f5b33261a2"
    },
    {
      "id": "3ee0ad9f-66d5-4356-80f3-65327be69c17",
      "name": "bis-choline tetrathiomolybdate",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "06f944ce-0d9e-48bd-8ab3-56f5b33261a2"
    },
    {
      "id": "54ecaf8a-a751-4a8e-bff1-b1fbd8bf5f61",
      "name": "Molybdenum",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "59d87f57-17e0-4766-8c62-3e5a3b7f75cd"
    },
    {
      "id": "597c932a-b010-436d-a4cc-e10231ad28b9",
      "name": "Paracetamol",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "6708b7c6-dc32-490b-9f37-fd59a4e491f7"
    },
    {
      "id": "333dd513-0f56-4ad7-8440-c2f6a49ebf8e",
      "name": "Acetaminophen",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "6708b7c6-dc32-490b-9f37-fd59a4e491f7"
    },
    {
      "id": "304cd5ab-5789-47af-bbe0-668537036d19",
      "name": "Ibuprofen",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "e449aa93-5021-4940-ae32-939483d0f78b"
    },
    {
      "id": "f0652a8a-f0c6-4950-8b63-5340982dcb8d",
      "name": "Zinc",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "e51c59c6-5da6-467b-977a-24b3810b3aab"
    },
    {
      "id": "65a7988f-05c7-4099-a87f-97b163c1a62f",
      "name": "Ammonium tetrathiomolybdate",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "789b6b4e-397a-4ba8-9e65-ccdb8955190d"
    }
  ],
  "strengths": [
    {
      "id": "b76d7117-2aa8-4cab-9494-b3a5ab877581",
      "instanceType": "Strength",
      "value": 15,
      "unit": "mg",
      "numerator": {
        "value": 15,
        "unit": "mg"
      }
    },
    {
      "id": "6eab7bad-6b38-40a5-aea3-6dfb10a551f0",
      "instanceType": "Strength",
      "value": 30,
      "unit": "mg",
      "numerator": {
        "value": 30,
        "unit": "mg"
      }
    },
    {
      "id": "b108c1fc-f684-4679-a4b3-b329e89188be",
      "instanceType": "Strength",
      "value": 60,
      "unit": "mg",
      "numerator": {
        "value": 60,
        "unit": "mg"
      }
    },
    {
      "id": "65a08401-17eb-4b9a-9333-8dc0faa87633",
      "instanceType": "Strength",
      "value": 1000,
      "unit": "mg",
      "numerator": {
        "value": 1000,
        "unit": "mg"
      }
    },
    {
      "id": "b0b29c24-52ae-440d-bc98-5f7fa9dbb0b3",
      "instanceType": "Strength",
      "value": 1200,
      "unit": "mg",
      "numerator": {
        "value": 1200,
        "unit": "mg"
      }
    }
  ],
  "timings": [
    {
      "id": "7c4a1be4-e482-45c4-bc89-c368ea669c0a",
      "name": "End of Study Visit Window",
      "type": "At",
      "unit": "days",
      "instanceType": "Timing",
      "value": 54,
      "relativeTo": "First Dose",
      "windowLower": -2,
      "windowUpper": 2
    },
    {
      "id": "f567ff03-cac4-4a1a-ad9d-5b2a386dbc05",
      "name": "Zinc Therapy Washout",
      "type": "Before",
      "unit": "days",
      "instanceType": "Timing",
      "value": 21,
      "relativeTo": "First Dose"
    },
    {
      "id": "c5bcd3bf-1351-43fd-802a-3ae36efba9d4",
      "name": "Chelator Therapy Washout",
      "type": "Before",
      "unit": "days",
      "instanceType": "Timing",
      "value": 4,
      "relativeTo": "First Dose"
    },
    {
      "id": "cfb82b41-dc3d-4652-b5eb-d3aba48f675a",
      "name": "Experimental Therapy Washout",
      "type": "Before",
      "unit": "days",
      "instanceType": "Timing",
      "value": 90,
      "relativeTo": "Screening"
    },
    {
      "id": "20fee21e-57ca-4d4c-853f-0bf642d272ea",
      "name": "Prescription Medication Washout",
      "type": "Before",
      "unit": "days",
      "instanceType": "Timing",
      "value": 14,
      "relativeTo": "First Dose",
      "windowUpper": -7
    },
    {
      "id": "9db60ce4-1476-468d-92f7-89642e687535",
      "name": "Non-Prescription Medication Washout",
      "type": "Before",
      "unit": "days",
      "instanceType": "Timing",
      "value": 7,
      "relativeTo": "First Dose",
      "windowUpper": -7
    },
    {
      "id": "62fe475e-fb94-457b-80c8-77cef22ba653",
      "name": "Alcohol Abstinence Prior to Dosing",
      "type": "Before",
      "unit": "hours",
      "instanceType": "Timing",
      "value": 48,
      "relativeTo": "First Dose"
    },
    {
      "id": "519f7ddd-d1c0-453f-9363-d8b76b7cef53",
      "name": "Registration",
      "type": "At",
      "unit": "days",
      "instanceType": "Timing",
      "value": -7,
      "relativeTo": "First Dose"
    },
    {
      "id": "f1c6e23c-b950-4750-b073-7bd20a24851a",
      "name": "First CRU Admission",
      "type": "At",
      "unit": "days",
      "instanceType": "Timing",
      "value": -8,
      "relativeTo": "First Dose"
    },
    {
      "id": "6d283dbc-0f2e-41a4-9dee-3f2f9d7507ce",
      "name": "Second CRU Admission",
      "type": "Between",
      "unit": "days",
      "instanceType": "Timing",
      "value": 22.5,
      "relativeTo": "First Dose",
      "windowLower": -0.5,
      "windowUpper": 0.5
    },
    {
      "id": "d3b563c9-1126-45f7-acf8-afa4fbdc5df7",
      "name": "Dose Titration to 30mg",
      "type": "At",
      "unit": "days",
      "instanceType": "Timing",
      "value": 29,
      "relativeTo": "First Dose"
    },
    {
      "id": "12e71b9a-27fc-4b8e-a363-2b759997040d",
      "name": "Pregnancy Testing Frequency",
      "type": "After",
      "unit": "weeks",
      "instanceType": "Timing",
      "value": 4,
      "relativeTo": "Previous Visit"
    },
    {
      "id": "0adddbdc-4342-4328-a5ac-52e9d6e56fe1",
      "name": "Pre-dose Fasting",
      "type": "Before",
      "unit": "hours",
      "instanceType": "Timing",
      "value": 10,
      "relativeTo": "First Dose"
    },
    {
      "id": "25441157-24bc-4b0f-ad3d-84ac2adf89c9",
      "name": "Post-dose Meal Delay",
      "type": "After",
      "unit": "hours",
      "instanceType": "Timing",
      "value": 2,
      "relativeTo": "First Dose"
    },
    {
      "id": "04313f78-c839-45bb-88fa-04806bb6d25d",
      "name": "Outpatient Dosing Window",
      "type": "At",
      "unit": "hours",
      "instanceType": "Timing",
      "value": 0,
      "relativeTo": "Previous Visit",
      "windowLower": -1,
      "windowUpper": 1
    },
    {
      "id": "0d526cbb-81b7-47dd-99e0-cfdcc9d09972",
      "name": "Weekly Safety Monitoring",
      "type": "After",
      "unit": "weeks",
      "instanceType": "Timing",
      "value": 1,
      "relativeTo": "Previous Visit"
    },
    {
      "id": "10640967-315e-4171-8c96-5f09ee909ea9",
      "name": "Tetrathiomolybdate Washout",
      "type": "Before",
      "unit": "years",
      "instanceType": "Timing",
      "value": 1,
      "relativeTo": "First Dose"
    }
  ],
  "conditions": [
    {
      "id": "54b9bf97-6077-404e-9d7b-6bcd1b54fcc8",
      "name": "Moderate Transaminase Elevation",
      "instanceType": "Condition",
      "description": "Criteria for moderate liver enzyme elevation requiring dose interruption.",
      "text": "ALT or AST > 3x and <= 5x ULN"
    },
    {
      "id": "3c81593e-d759-473a-8513-97165a818233",
      "name": "Severe Transaminase Elevation",
      "instanceType": "Condition",
      "description": "Criteria for severe liver enzyme elevation requiring discontinuation.",
      "text": "ALT or AST > 5x ULN"
    },
    {
      "id": "fbc92d68-1b02-47bc-819c-f621fd9738bf",
      "name": "Potential Liver Injury (Hy's Law)",
      "instanceType": "Condition",
      "description": "Criteria for potential drug-induced liver injury requiring dose interruption.",
      "text": "Bilirubin > 2x ULN accompanied by ALT > 3x ULN"
    },
    {
      "id": "79bc0b8b-f1d3-42db-b56d-8db5d1b9d7a7",
      "name": "Anemia",
      "instanceType": "Condition",
      "description": "Criteria for anemia requiring dose reduction.",
      "text": "Hemoglobin < 10 g/dL"
    },
    {
      "id": "9d132f5a-0e3a-4aa1-9273-cfe78888f9a9",
      "name": "Thrombocytopenia",
      "instanceType": "Condition",
      "description": "Criteria for low platelets requiring dose reduction.",
      "text": "Platelets < 100,000/mm3"
    },
    {
      "id": "753eaf4f-3fc5-4eeb-9278-b29aa6a42327",
      "name": "Neutropenia",
      "instanceType": "Condition",
      "description": "Criteria for low neutrophils requiring dose reduction.",
      "text": "Neutrophils > 30% decrease from baseline and below reference range"
    },
    {
      "id": "478f87c1-5717-4918-9eeb-358391ed2885",
      "name": "Neurologic Worsening",
      "instanceType": "Condition",
      "description": "Criteria for neurologic worsening requiring evaluation for dose modification.",
      "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
    },
    {
      "id": "bbaa0aa5-f93b-49a3-85a8-bd782a88eaf7",
      "name": "Psychiatric Worsening",
      "instanceType": "Condition",
      "description": "Criteria for psychiatric worsening requiring evaluation for dose modification.",
      "text": "Evidence of clinically significant acute psychiatric worsening"
    },
    {
      "id": "b2f7c46c-d450-4030-813d-42b68467d05d",
      "name": "SRC Safety Review for Titration",
      "instanceType": "Condition",
      "description": "Condition for dose escalation to 30 mg/day.",
      "text": "The Safety Review Committee (SRC) will review available safety data through Day 23 for each participant before titration to 30 mg/day."
    },
    {
      "id": "3645f0ba-456d-41de-b15b-e45a6b2aa224",
      "name": "Outpatient Period Extension",
      "instanceType": "Condition",
      "description": "Adaptive design feature allowing for extension of the outpatient period.",
      "text": "The Outpatient Period during Treatment Period 1 may be extended up to an additional 14 days with Investigator approval."
    }
  ],
  "transitionRules": [
    {
      "id": "5827df44-d302-4bc5-9347-44e91eda769f",
      "name": "Dose Titration to 30mg",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "On Day 29, participants will be administered ALXN1840 at 30 mg/day, following a 28-day period at 15 mg/day, pending SRC safety review."
    },
    {
      "id": "aa61b12a-72d0-4f91-86ee-0f4c574cddaf",
      "name": "Dose Interruption for Moderate Transaminase Elevation",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "If ALT or AST > 3x and <= 5x ULN, temporarily interrupt dosing."
    },
    {
      "id": "da3f0727-322a-4ece-a1d4-6372f0ccdf79",
      "name": "Discontinuation for Severe Transaminase Elevation",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "If ALT or AST > 5x ULN, discontinue study intervention."
    },
    {
      "id": "205e844b-2ff6-45ac-a6e1-0c3cf655df55",
      "name": "Dose Reduction for Anemia or Thrombocytopenia",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "If Hemoglobin < 10 g/dL or Platelets < 100,000/mm3, reduce dose to previous dose level or to 15 mg QOD if on 15 mg QD."
    },
    {
      "id": "d7f7619a-e4f4-45d4-8bce-0fa4f913119d",
      "name": "Dose Reduction for Neutropenia",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "If Neutrophils > 30% decrease from baseline and below reference range, reduce dose to previous dose level or to 15 mg QOD if on 15 mg QD."
    },
    {
      "id": "b1dfaa4b-641b-4b0a-9366-7f59d3a27381",
      "name": "Dose Interruption for Potential Liver Injury",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "If Bilirubin > 2x ULN and ALT > 3x ULN, temporarily interrupt dosing."
    },
    {
      "id": "19d19e0d-46cd-4f8e-90ed-67267916ba11",
      "name": "Dose Modification for Neurologic or Psychiatric Worsening",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "Investigator and Alexion Medical Monitor will evaluate the need for dose modification (interruption, increase or decrease) based on neurologic or psychiatric worsening."
    },
    {
      "id": "555c84dc-9aa8-4211-a6e8-3bf9c9a1d339",
      "name": "Remain on 15mg Dose due to Safety",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "Participants may remain on the 15 mg/day dose for the duration of the study if there are safety concerns that prevent up-titration."
    }
  ],
  "scheduleTimelineExits": [
    {
      "id": "ff04f55a-ef3b-4d57-bb97-2d2bb36ce9e8",
      "name": "Study Completion",
      "exitType": "Completion",
      "instanceType": "ScheduleTimelineExit",
      "description": "Participant has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities (EOS Visit)."
    },
    {
      "id": "03d74e5d-8444-4cc1-84bb-ed270ae82ee5",
      "name": "Participant Withdrawal of Consent",
      "exitType": "Early Termination",
      "instanceType": "ScheduleTimelineExit",
      "description": "A participant may withdraw from the study at any time at his/her own request."
    },
    {
      "id": "4e8364d0-05e2-47a8-b89c-f5a638d9f8f6",
      "name": "Investigator Discretion Withdrawal",
      "exitType": "Early Termination",
      "instanceType": "ScheduleTimelineExit",
      "description": "Participant may be withdrawn at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
    },
    {
      "id": "023eee6e-17ff-49ff-9415-f7c9d9766c58",
      "name": "Discontinuation for Serious Hypersensitivity Reaction",
      "exitType": "Early Termination",
      "instanceType": "ScheduleTimelineExit",
      "description": "Participants must be considered for discontinuation from study intervention for a serious hypersensitivity reaction."
    },
    {
      "id": "8e3a2f4f-db94-40c2-97e6-944130187864",
      "name": "Discontinuation for Severe Uncontrolled Infection",
      "exitType": "Early Termination",
      "instanceType": "ScheduleTimelineExit",
      "description": "Participants must be considered for discontinuation from study intervention for a severe uncontrolled infection."
    },
    {
      "id": "a0da48d3-3ca8-4d67-832c-b5c51cdf74a3",
      "name": "Discontinuation for Use of Disallowed Medication",
      "exitType": "Early Termination",
      "instanceType": "ScheduleTimelineExit",
      "description": "Participants must be considered for discontinuation from study intervention for use of a disallowed medication."
    },
    {
      "id": "1a5b9bb4-bce6-4225-9037-2bd8f40f5bdc",
      "name": "Discontinuation for Pregnancy",
      "exitType": "Early Termination",
      "instanceType": "ScheduleTimelineExit",
      "description": "Participants must be considered for discontinuation from study intervention for pregnancy or planned pregnancy."
    },
    {
      "id": "156ce1c9-014a-4aea-858a-391ef302bd74",
      "name": "Lost to Follow-up",
      "exitType": "Early Termination",
      "instanceType": "ScheduleTimelineExit",
      "description": "A participant is considered lost to follow-up if they repeatedly fail to return for scheduled visits and are unable to be contacted by the study site."
    }
  ],
  "analysisPopulations": [
    {
      "id": "0a4a6876-54ad-410e-9f2f-a8118c50ea68",
      "name": "Screened Set",
      "populationType": "Disposition",
      "instanceType": "AnalysisPopulation",
      "populationDescription": "Definition not found in the provided text. The definition is expected in Section 6.1 on page 17."
    },
    {
      "id": "bccb191b-62c5-420e-93fd-b6673edce14c",
      "name": "Enrolled Set",
      "populationType": "Disposition",
      "instanceType": "AnalysisPopulation",
      "populationDescription": "Definition not found in the provided text. The definition is expected in Section 6.2 on page 17."
    },
    {
      "id": "19424202-5652-491d-9fb8-69c4b125b8a4",
      "name": "Full Analysis Set",
      "populationType": "Efficacy",
      "instanceType": "AnalysisPopulation",
      "label": "FA",
      "populationDescription": "Definition not found in the provided text. The definition is expected in Section 6.3 on page 17."
    },
    {
      "id": "eedf8a99-ed01-4def-8911-c4b4aaaa29ca",
      "name": "Per Protocol Set",
      "populationType": "Efficacy",
      "instanceType": "AnalysisPopulation",
      "label": "PP",
      "populationDescription": "Definition not found in the provided text. The definition is expected in Section 6.4 on page 17."
    },
    {
      "id": "08c1c976-6406-4352-aff5-12c325611fbb",
      "name": "Safety Set",
      "populationType": "Safety",
      "instanceType": "AnalysisPopulation",
      "label": "SAF",
      "populationDescription": "Definition not found in the provided text. The definition is expected in Section 6.5 on page 17."
    },
    {
      "id": "d2af6a30-c54b-4a3a-9321-9f8e71518144",
      "name": "Pharmacokinetic Analysis Set",
      "populationType": "PK/PD",
      "instanceType": "AnalysisPopulation",
      "label": "PK Set",
      "populationDescription": "Definition not found in the provided text. The definition is expected in Section 6.6 on page 17."
    },
    {
      "id": "8898a2cf-8bb1-4b25-b456-e441e08eb09e",
      "name": "Pharmacodynamic Analysis Set",
      "populationType": "PK/PD",
      "instanceType": "AnalysisPopulation",
      "label": "PD Set",
      "populationDescription": "Definition not found in the provided text. The definition is expected in Section 6.7 on page 17."
    }
  ],
  "documentContentReferences": [
    {
      "id": "0e6377b0-9977-4848-91c9-68bdea9b2e44",
      "name": "Amendment Summary to SoA",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "1.3",
      "sectionTitle": "Schedule of Activities (SoA), Table 1",
      "description": "Reference from the Protocol Amendment Summary table to the SoA regarding an added footnote."
    },
    {
      "id": "8ff8b9d7-0153-41f7-9910-631394d92deb",
      "name": "Amendment Summary to Study Assessments",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8",
      "sectionTitle": "Study Assessments and Procedures",
      "description": "Reference from the Protocol Amendment Summary table to Section 8 for details on procedures at US screening-only sites."
    },
    {
      "id": "54dee117-ca8d-4779-8369-6678c4ce4fd7",
      "name": "COVID-19 Vaccine Risk Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "10.5",
      "sectionTitle": "COVID-19 Vaccine Risk Assessment",
      "description": "Reference from Section 2.3.1.1 to Section 10.5 for potential risks and mitigation measures due to COVID-19 vaccine."
    },
    {
      "id": "1f999c30-af60-43e5-a6b5-1ae9931bf164",
      "name": "Risk Mitigation Dose Modification Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "6.6",
      "sectionTitle": "Dose Modification",
      "description": "Multiple references from Table 3 (Potential Risks and Mitigation Strategy) to Section 6.6 for dose modification or discontinuation strategies."
    },
    {
      "id": "cfd4a875-f418-40f0-b229-64092c95b266",
      "name": "Risk Data Source Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "N/A",
      "sectionTitle": "Investigator’s Brochure",
      "description": "Multiple references from Table 3 to the Investigator's Brochure (IB) as the source of risk data."
    },
    {
      "id": "f51d19fa-76fa-4705-88a8-d071d2fb539f",
      "name": "Adaptive Design Features Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Table 4",
      "sectionTitle": "Adaptive Protocol Features",
      "description": "Reference from Section 4.1 to Table 4, which describes the adaptive features of the study design."
    },
    {
      "id": "33d06cd3-f032-4527-9199-c0e9bbe0d8cc",
      "name": "Adaptive Dose Modification Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Table 7",
      "sectionTitle": "ALXN1840 Dose Modifications for Individual Participants",
      "description": "Reference from Table 4 (Adaptive Protocol Features) to Table 7 for dose modification criteria."
    },
    {
      "id": "3b0d88a2-6ab7-42b6-9ee2-1237bd157ec2",
      "name": "Exclusion Criteria Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "5.2",
      "sectionTitle": "Exclusion Criteria",
      "description": "Reference from Table 5 (Participant Lifestyle Considerations) regarding blood donation restriction to the exclusion criteria in Section 5.2."
    },
    {
      "id": "d2934e8f-8636-46b5-ab4a-6ab3695af600",
      "name": "Contraception Guidance Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "10.4",
      "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
      "description": "Reference from Table 5 (Participant Lifestyle Considerations) to Section 10.4 for details on appropriate contraceptive methods."
    },
    {
      "id": "967bc407-7b68-4bae-a826-9f68f33e533f",
      "name": "Inclusion Criteria Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "5.1",
      "sectionTitle": "Inclusion Criteria",
      "description": "Reference from Table 5 (Participant Lifestyle Considerations) to Section 5.1 for contraception start times."
    },
    {
      "id": "2dee6964-a77a-4244-ac89-60d6da90657b",
      "name": "Intervention Discontinuation Procedures",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "1.3",
      "sectionTitle": "Schedule of Activities (SoA)",
      "description": "Reference from Section 7.1 to the SoA (Section 1.3 and Table 1) for data to be collected at the time of study intervention discontinuation."
    },
    {
      "id": "ca717732-c34d-4110-81f1-032cde118121",
      "name": "Discontinuation for Liver Function",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "6.6",
      "sectionTitle": "Dose Modification",
      "description": "Reference from Section 7.1 to the Dose Modification criteria in Section 6.6 regarding discontinuation for abnormal liver function."
    },
    {
      "id": "c40f0061-ead6-44ba-b6eb-f39d6137b41b",
      "name": "Discontinuation for Pregnancy",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8.2.6",
      "sectionTitle": "Pregnancy",
      "description": "Reference from Section 7.1 to Section 8.2.6 regarding discontinuation due to pregnancy."
    },
    {
      "id": "640db0c3-9218-4a90-9e0c-9265cbea0212",
      "name": "Participant Withdrawal Procedures",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "1.3",
      "sectionTitle": "Schedule of Activities (SoA)",
      "description": "Reference from Section 7.2 to the SoA for data to be collected at an early discontinuation visit."
    },
    {
      "id": "b7a7bd0a-2018-4664-87df-59a2991e2da6",
      "name": "ECG Schedule Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "1.3",
      "sectionTitle": "Schedule of Activities (SoA)",
      "description": "Reference from Section 8.2.3 to the SoA for the schedule of 12-lead ECGs."
    },
    {
      "id": "e3247a93-1a12-487d-a2f8-cb87e546a085",
      "name": "QTc Withdrawal Criteria Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "7",
      "sectionTitle": "DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL",
      "description": "Reference from Section 8.2.3 to Section 7 for QTc withdrawal criteria."
    },
    {
      "id": "d294d81f-f812-4ca0-838d-e4e2eb9a5a43",
      "name": "Clinical Lab Tests List Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "10.2",
      "sectionTitle": "Clinical Laboratory Tests",
      "description": "Reference from Section 8.2.4 to Section 10.2 for the list of clinical laboratory tests to be performed."
    },
    {
      "id": "01a4541f-e395-436d-b4f0-38db980b20f6",
      "name": "AE/SAE Procedures Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "10.3",
      "sectionTitle": "Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
      "description": "Multiple references from Section 8.3 to Section 10.3 for procedures on recording, evaluating, and reporting AEs and SAEs."
    },
    {
      "id": "3880b8a8-d6e9-4606-a319-d13c862dcd35",
      "name": "Lost to Follow-up Definition",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "7.3",
      "sectionTitle": "Lost to Follow-up",
      "description": "Reference from Section 8.3.3 to Section 7.3 for the definition of 'lost to follow-up'."
    },
    {
      "id": "d116ce78-7420-43e6-96e9-b33a1c28804a",
      "name": "Genetic Testing Clarification",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8.7",
      "sectionTitle": "Genetics",
      "description": "Reference from Section 8.3.6 to Section 8.7 to clarify that biobanked samples will not be used for genetic testing."
    },
    {
      "id": "878d0e2e-990d-4946-8df7-e0cbfe084346",
      "name": "PK/PD Sample Collection Schedule",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Table 1",
      "sectionTitle": "Schedule of Activities",
      "description": "References from Sections 8.5 and 8.6 to the SoA (Table 1) for the schedule of PK and PD sample collection."
    },
    {
      "id": "a1d8098c-1ecf-4ef8-912e-979973864ed5",
      "name": "Biomarker Measurement Details",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8.1.1",
      "sectionTitle": "Copper and Molybdenum Balance Measurements",
      "description": "References from Sections 8.5 and 8.8 to Section 8.1.1 for details on copper and molybdenum measurements in various samples."
    },
    {
      "id": "fb320573-3633-4338-9d44-d0a042f11177",
      "name": "Analysis Populations Definition",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Table 8",
      "sectionTitle": "Populations for Analysis",
      "description": "Reference from Section 9.3 to Table 8, which defines the populations for analyses."
    }
  ],
  "commentAnnotations": [
    {
      "id": "8f277ed2-bf6e-4914-a0d2-dca804dfc9a1",
      "text": "This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union, the US Food and Drug Administration’s (FDA) regulation at 21 CFR part 312.30(b), and any applicable local regulations.",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE",
      "pageNumber": 3
    },
    {
      "id": "cde5b917-b11e-42cd-9b45-7d4343ee7145",
      "text": "Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IB = Investigator’s Brochure; PK = pharmacokinetics; WD = Wilson disease.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Table 3: Potential Risks and Mitigation Strategy",
      "pageNumber": 21
    },
    {
      "id": "4b340a50-7531-43b1-bd14-41bb93799b3b",
      "text": "Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of Activities.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Table 5: Participant Lifestyle Considerations",
      "pageNumber": 35
    },
    {
      "id": "6bc2150b-1db1-4339-991b-b87f5ef3e776",
      "text": "Abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK = pharmacokinetic.",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Table 8: Populations for Analysis",
      "pageNumber": 51
    },
    {
      "id": "254b2c74-2a0d-4a91-9389-77ff1a96cbbd",
      "text": "Note: total molybdenum and PUF molybdenum concentration-time profiles on Day 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr) and subtracted from the observed Day 29 concentration-time profiles after the first 30 mg",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "9.4.4. Pharmacokinetic, Pharmacodynamic, and Biomarker Analyses",
      "pageNumber": 53
    }
  ],
  "studyDefinitionDocumentVersions": [
    {
      "id": "f569aec0-b06a-4d80-ac6e-39eba5a871cd",
      "versionNumber": "3.1 (US)",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2022-03-18",
      "description": "Current protocol version. Clarifies study procedures in the US to facilitate recruitment and lessen participant inconvenience.",
      "amendmentNumber": "Amendment 3.1 (US)"
    },
    {
      "id": "f461a183-e31f-4f13-a5ec-9b3e0df7d071",
      "versionNumber": "3",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2021-08-31",
      "description": "Previous approved version.",
      "amendmentNumber": "Amendment 3"
    },
    {
      "id": "77a7f109-f8f5-43b3-b50c-e2ac7007b5f5",
      "versionNumber": "2",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2021-03-19",
      "description": "Previous approved version.",
      "amendmentNumber": "Amendment 2"
    },
    {
      "id": "9deb7e3e-7aa0-4588-863d-1b996c99a24c",
      "versionNumber": "1",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2020-08-18",
      "description": "Previous approved version.",
      "amendmentNumber": "Amendment 1"
    },
    {
      "id": "1e3a712a-98d2-4ec8-808b-772d4c803a2a",
      "versionNumber": "Original",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2020-05-12",
      "description": "Original approved protocol.",
      "amendmentNumber": "Original Protocol"
    }
  ],
  "studyAmendmentImpacts": [
    {
      "id": "a9595445-f8e1-46d5-b9cb-5ffae8974598",
      "amendmentId": "ec6d80f2-5d6e-4c5e-a7c2-72a1484b5574",
      "affectedSection": "Section 1.3 Schedule of Activities (SoA), Table 1",
      "impactLevel": "Major",
      "instanceType": "StudyAmendmentImpact",
      "description": "Addition of a footnote to the Schedule of Activities to reference US-specific screening procedures."
    },
    {
      "id": "e57e373a-6739-4544-bb38-7685c38f3a21",
      "amendmentId": "ec6d80f2-5d6e-4c5e-a7c2-72a1484b5574",
      "affectedSection": "Section 4.2 Scientific Rationale for Study Design",
      "impactLevel": "Administrative",
      "instanceType": "StudyAmendmentImpact",
      "description": "A number of days was changed to align text with other sections of the protocol."
    },
    {
      "id": "b4e37942-0b26-4253-b5b3-b68b97863fe4",
      "amendmentId": "ec6d80f2-5d6e-4c5e-a7c2-72a1484b5574",
      "affectedSection": "Section 8 Study Assessments and Procedures",
      "impactLevel": "Major",
      "instanceType": "StudyAmendmentImpact",
      "description": "Addition of procedures allowing US sites to perform screening-only activities to facilitate recruitment."
    }
  ],
  "studyAmendmentReasons": [
    {
      "id": "953d0b20-99a4-4860-b4f8-c2d69fe0bb47",
      "amendmentId": "ec6d80f2-5d6e-4c5e-a7c2-72a1484b5574",
      "reasonText": "To clarify study procedures occurring across different sites in the US, so as to facilitate participant recruitment across different regions of the US, and to lessen inconvenience for participants without compromising the quality of the study.",
      "category": "Operational",
      "isPrimary": true,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "117cb7ac-53c6-4961-9480-0882663c999b",
      "amendmentId": "ec6d80f2-5d6e-4c5e-a7c2-72a1484b5574",
      "reasonText": "To align the number of days with the mention of zinc discontinuation elsewhere in the protocol.",
      "category": "Administrative",
      "isPrimary": false,
      "instanceType": "StudyAmendmentReason"
    }
  ],
  "studyChanges": [
    {
      "id": "90ccd720-8707-4364-a2dc-d2b4fde566a3",
      "amendmentId": "ec6d80f2-5d6e-4c5e-a7c2-72a1484b5574",
      "changeType": "Addition",
      "instanceType": "StudyChange",
      "sectionNumber": "1.3",
      "summary": "Addition of text to the footnote of Table 1 to state that procedures specific to screening sites (only in the US) are detailed in Section 8."
    },
    {
      "id": "a2754c20-b714-4da8-8239-2a7c573029ab",
      "amendmentId": "ec6d80f2-5d6e-4c5e-a7c2-72a1484b5574",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "4.2",
      "beforeText": "...the inhibitory effect of zinc on intestinal copper absorption is expected to be minimal 30 days after discontinuation of zinc.",
      "afterText": "...the inhibitory effect of zinc on intestinal copper absorption is expected to be minimal 21 days after discontinuation of zinc.",
      "summary": "The number of days for the expected minimal inhibitory effect of zinc was changed from 30 to 21."
    },
    {
      "id": "67b8d2fd-ea1b-4bf0-8916-e710bfa521b8",
      "amendmentId": "ec6d80f2-5d6e-4c5e-a7c2-72a1484b5574",
      "changeType": "Addition",
      "instanceType": "StudyChange",
      "sectionNumber": "8",
      "summary": "Addition of text applicable only to the US that details the possibility for sites in the US to only perform screening procedures and not any of the remaining study procedures."
    }
  ],
  "computationalExecution": {
    "ready": true,
    "supportedSystems": [
      "EDC",
      "ePRO",
      "CTMS",
      "RTSM"
    ],
    "validationStatus": "complete"
  }
}